2022 UK Conference - BSACI Conference 2022

EICC Edinburgh25-27 April 2022

World Allergy Organization & BSACI

2022 UK ConferenceAnnual Conference Programme

wao-bsaci.org

Aimmune Therapeutics is proud to be a sponsor at the WAO & BSACI 2022 UK conference and have several engaging and topical sessions for delegates to participate in. Within the programme for this conference, we have organised and funded the meetings described below.

Treating peanut allergy with oral immunotherapy: implementation and practical experienceJoin us for a discussion-based panel session sharing expert insight into use of PALFORZIA® in peanut allergy

MONDAY 25 APRIL 2022 | 17:45–18:45SYMPOSIUM:

Meet in small groups with your colleagues to discuss practicalities of identifying eligible patients and optimising treatment of peanut allergy with PALFORZIA®

25–27 APRIL 2022 | SEE BOOTHFOR TIMESMEET-THE-EXPERT:

VISIT OUR BOOTH FOR MORE INFORMATION - STAND 2B

PALF-PM-UK-0059 | March 2022 All meeting events and booth content are intended for healthcare professionals only.

PALFORZIA® is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. PALFORZIA®

may be continued in patients 18 years of age and older. PALFORZIA® should be used in conjunction with a peanut-avoidant diet.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Aimmune Therapeutics UK Ltd at [email protected].

Please see prescribing information here

BSACI, British Society for Allergy & Clinical Immunology; WAO, World Allergy Organization.

Learn more aboutthe first licensed

treatmentfor peanut allergy in the UK and EUPALFORZIA® NEW AND NOW APPROVED

3wao-bsaci.org

Contents

4A warm welcome

6WAO-BSACI 2022 Committees

10About WAO-BSACI

11Conference information

16Venue floor plan

18Safety measures

24ProgrammeDay 1: Monday 25th April 2022

27 ProgrammeDay 2: Tuesday 26th April 2022

33Programme Day 3:Wednesday 27th April 2022

35Speciality group meetings

36Poster abstracts

50Invited speakers

84Working with our Industry Partners

87Sponsors and exhibitors

97Industry sponsored satellite symposia

100Exhibition floor plan

4 WAO and BSACI 2022 UK Conference Programme

Dear Friends and Colleagues,

Welcome to the WAO & BSACI 2022 UK Conference in the historical city of Edinburgh. The United Kingdom (UK) last hosted a WAO conference in 1982, and we now have the pleasure to meet again in the UK after 40 years, for a conference that will be an experience to remember.

Following a very successful BSACI Annual Conference in 2021, we have prepared a rich and robust programme which will be delivered by a host of international experts to inspire and engage you. The conference highlights the allergy field on a global scale and endorses innovation. We will also focus on the effect of the environment and climate on allergy, as the new decade presents us with several global challenges from these viewpoints.

As it is fitting for a WAO conference, we have focused on collaborations with national and international societies, with a Joint Society session featured on each day. We open with the European Academy of Allergy and Clinical Immunology (EAACI) and the upper respiratory system on the first day, continue with the American Academy of Allergy Asthma and Immunology (AAAAI) and inborn errors of immunity on the second day, and close with the Japanese Society of Allergology (JSA) and atopic dermatitis on the third day. We further highlight the importance of input from all parts of society, and offer a platform to key UK charities, the Anaphylaxis Campaign, Allergy UK and the Natasha Allergy Research Foundation (NARF), to discuss updates in informing and protecting the allergic public. As we are still trying to leave the pandemic behind us, COVID and the COVID vaccine remain highly relevant and will be showcased and discussed. There will also be several informative workshops where practical issues of our everyday practice will be highlighted in an engaging, hands-on environment.

The combined expertise of BSACI and WAO, alongside the support of our sister societies guarantee a conference that will be one of the scientific highlights of 2022 for the field. The program features several exciting paediatric and adult sessions, focuses throughout on the global aspect of allergy, and caters for clinicians, scientists and allied health professionals who work with children and adults alike. We provide a platform to British and international speakers of global calibre who are at the cutting edge of their respective fields to deliver high-quality talks for all issues around Allergy & Immunology. Professor Graham Roberts, BSACI President, will open the Keynote Plenary on the first day

A warm welcome

5wao-bsaci.org

by discussing a comprehensive approach to managing food allergy, followed by Professor Motohiro Ebisawa, WAO President who will talk about oral and sublingual immunotherapy for food allergy. Professor Nikolaos Papadopoulos, EAACI Past President, will close the Plenary by discussing viral infections and allergy interactions in the post-COVID Era. The program features throughout a number of sessions that highlight the effect of environment on allergy, culminating in the Plenary of Environmental Exposures on the third day, where Professor Sir Stephen Holgate and Professor Jurgen Schwarze will deliver keynote lectures on the effect of pollution, the climate, helminths and viruses on allergy. The conference will close with a Year in Review session supported by WAO, BSACI, and our sister societies, which celebrates the strong bonds that bind us. Current, past and elect Presidents of WAO, BSACI, EAACI, AAAAI and JSA will join together to Chair and speak in a session that highlights this year’s advances and breakthroughs in biologics, anaphylaxis, immunotherapy and everything that has the potential to change our clinical practice. This will be a once-in-a-lifetime session not to be missed.

We want to extend our thanks to the WAO & BSACI Steering Committee, WAO & BSACI Programme Planning Committee, especially Fiona Rayner (BSACI Chief Executive) and her team, Justin Dodge (WAO Chief Executive), Dr Tammy Rothenberg, Dr Olympia Tsilochristou, Rebecca Batt, Dr Matt Doyle and Dr. Isabel Skypala. Also, the BSACI Trustees and Council for their guidance throughout the planning of this event, BSACI Marketing and Communications Manager Louise Colonnese, the WAO team and our professional conference partners at Medivents, Karen Anthony, Lucie Flint and Gemma Wilkins. We would also like to thank our corporate sponsors and exhibitors, and our charity partners Allergy UK, Anaphylaxis Campaign and Natasha Allergy Research Foundation (NARF) for their support. Please take the time to visit the stands in the exhibition area. Also, make the most of your visit to Edinburgh and tour the famous Edinburgh Castle, take in the sights of the city, or play a round of golf. There is lots to see and do in historic Edinburgh!

We hope that you will find the conference a rewarding experience, and that you enjoy the opportunity to connect with friends and colleagues in person.

Professor Graham Roberts

BSACI President

Dr George Gkimpas

Dr Natasha Gunawardana

Scientific Programme Co-Leads Deputy Scientific Leads

Professor Bryan Martin

Dr Nandinee Patel

Professor Motohiro Ebisawa

WAO President


WAO-BSACI 2022 Committees

World Allergy Organization Board of Directors

To view the committee conflict of interest statements please click here

Motohiro Ebisawa, President, Japan

Bryan Martin, President-Elect, USA

Mário Morais-Almeida, Secretary-General / Treasurer, Portugal

Ignacio J. Ansotegui, Past-President, Spain

Officers

Members-at-LargeJonathan A. Bernstein, USA

Luis Caraballo (ex-Officio), Colombia

Yoon-Seok Chang,Republic of Korea

Manana Chikhladze, Georgia

Adnan Custovic, UK

Alessandro Fiocchi, Vatican City

Sandra N González-Díaz, México

Luciana Kase Tanno,France

Michael Levin,South Africa

José Antonio Ortega-Martell (ex-Officio), Mexico

David B. Peden, USA

Philip W. Rouadi, Lebanon

James L. Sublett, USA

Lianglu Wang, People's Republic of China

Gary W.K. Wong, Hong Kong

Anahí Yáñez, Argentina

BSACI Council

Graham Roberts, BSACI President

Adam Fox, Past President

Deb Marriage, Secretary

Sue Leech, Treasurer

Trustee Directors

Steve Jenkins

George Gkimpas

Lucy Common

Dinusha Chandratilleke

Louise Michaelis

Rubaiyat Haque

Sophie FarooqueElected Members of Council

7wao-bsaci.org

Mich Lajeunesse, Chair of BRIT Registry Committee

Hannah Kramer, Chair of Nurses Committee

Nick Makwana,Chair of Paediatric Allergy Committee

Paul Ciclitira and Steve Jenkins Co-Chairs of Adult Allergy Committee

David Luyt, Chair of BSACI Standards of Care Committee

Tomaz Garcez, Chair of the Clinical Immunology Committee

Matt Doyle, Chair of Primary Care Committee

Dr Richard Pumphrey, Chair of the Anaphylaxis Steering Committee

Representatives and Leads of Committees

Louise Savic,Expert Working Party lead for Improving the provision of care in perioperative allergy

M Thirumala Krishna, Equality Diversity & Inclusivity Group Lead

Rebecca Knibb, Psychology Working Group Lead

Andrew Whyte, Rep on the RCP MSB

Michael Rudenko, EAACI Rep

Helen Smith, BSACI Ethics Champion

Hannah Hunter, Representative of the FASG of the BDA

Neha Christian/Dr C Alviani, Junior Members Representatives

Elizabeth Griffiths, Chair of Allergy Specialist Advisory Committee

Pamela Ewan, Allergy Services Lead and Co-Chair of the NASG

Judith Holloway,Chair of BSACI Allergy Education Network

Co-opted Members

Erika Harnik, Editor of Allergy Update

Bob Boyle, Co-Editor in Chief, Clinical and Experimental Allergy

Mohamed Shamji, Co-Editor in Chief, Clinical and Experimental Allergy

Appointed Members

WAO/BSACI Steering CommitteeGraham Roberts,Co-Chair, BSACI

Motohiro Ebisawa, Co-Chair, WAO

Ignacio J. Ansotegui, Spain

Nicola Braithwaite, BSACI Scientific Programme Planning (BSACI Past Secretary)

Adnan Custovic, UK

Adam Fox, Past President, BSACI

George Gkimpas, UK, Joint Scientific Programme Lead, BSACI

Bryan Martin, USA, Joint Scientific Programme Lead, BSACI

Mário Morais-Almeida, Portugal

Susan Leech,Treasurer, BSACI

Shuaib Nasser, BSACI Representative, UK


WAO/BSACI Programme Planning Committee

Bryan Martin, Co-Chair, USA

George Gkimpas, Co-Chair, UK

Graham Roberts, UK

Motohiro Ebisawa, Japan

Ignacio J. Ansotegui, Spain

Rebecca Batt, UK

Jonathan A. Bernstein, USA

Nicola Brathwaite, UK

Adnan Custovic, UK

Matt Doyle, UK

Stephen Durham,UK

Adam Fox, UK

Tomaz Garcez, UK

Natasha Gunawardana,UK

Susan Leech, UK

Michael Levin, South Africa

Tom Marrs, UK

Mário Morais-Almeida, Portugal

Shuaib Nasser, UK

Nandinee Patel, UK

Phillip W. Rouadi, Lebanon

Isabel Skypala,UK

Gary Wong, Hong Kong

Anahí Yáñez, Argentina

BSACI Local Organising CommitteeGeorge Gkimpas, Joint Scientific Programme Lead, BSACI

Nandinee Patel, Scientific Joint Deputy, Programme lead, BSACI

Natasha Gunawardana, Scientific Joint Deputy, Programme Lead, BSACI

Rebecca Batt, Nurse Representative

Louise Colonnese, Marketing and Communications Manager, BSACI

Matt Doyle, Primary Care Lead

Catherine Hyland, Managing Editor, CEA

Hannah Kramer, Nurse Representative

Fiona Rayner,CEO, BSACI

Tammy Rothenberg, Abstracts Lead

Isabel Skypala, Dietetic Representative

Olympia Tsilchristou, Deputy Abstracts Lead

BSACI would like to say a special thank you to Justin Dodge WAO Chief Executive for his insight and experience in helping with the direction and smooth running of the conference.


WAOThe World Allergy Organization (WAO) is an international umbrella organization whose members consist of 108 regional and national allergology and clinical immunology societies from around the world. By collaborating with member societies, WAO provides direct educational outreach programs, symposia and lectureships to members in nearly 100 countries around the globe.www.worldallergy.org

BSACIThe British Society for Allergy & Clinical Immunology (BSACI) is the national, professional and academic society which represents the specialty of allergy at all levels. Its aim is to improve the management of allergies and related diseases of the immune system in the United Kingdom, through education, training and research. www.bsaci.org

About WAO-BSACI

11wao-bsaci.org

Conference InformationVenueEdinburgh International Conference Centre (EICC)The Exchange, 150 Morrison St, Edinburgh, EH3 8EET: 0131 300 3000 W: eicc.co.uk

LanguageEnglish is the official language of the conference.

Registration deskThe registration desk is located in the Strathblane Hall and will be open during the following hours:

Monday 25th April 07:30 – 19:30Tuesday 26th April 07:30 – 19:30Wednesday 27th April 07:30 – 13:35

Conference name badgesPlease wear your name badge at all times. All participants are required to wear badges when attending sessions, social events and when entering the exhibition. If you lose your badge, please go to the registration desk and a new one will be made for you.

Exhibition opening timesThe exhibition is located in the Cromdale Hall and Foyer on Level -2. The exhibition opening hours are as follows:Monday 25th April 08:00 – 17:45 Tuesday 26th April 08:00 – 17:45Wednesday 27th April 08:00 – 11:00

Lunches and refreshments

Tea, coffee and lunches will be served during the official breaks within the Cromdale Hall and Foyer L-2.

Mobile phones, filming and photography

As a courtesy to speakers and other participants, all mobile phones should be switched to silent before entering scientific sessions. Any other electronic devices, such as cameras, laptops and tablets should also be turned to silent. Photographs of the scientific sessions, social events and exhibition areas will be taken throughout the conference for use on the BSACI website. If you do not want to be photographed, please let the photographer know.


Social Programme

Welcome ReceptionMonday 25th April 18:45 - 19:45Dress code CasualVenue Edinburgh International Conference

Centre (EICC), Strathblane HallThe Exchange, 150 Morrison St, Edinburgh, EH3 8EET: 0131 300 3000 W: eicc.co.uk

Please join us for nibbles and a welcome drink on the evening of 25th April. A limited number of tickets will be available for purchase onsite at the Conference registration desk at £15 including VAT.

The WAO/BSACI Presidents Dinner will take place in the historic building of The Royal College of Surgeons of Edinburgh in the Surgeons Quarter in the centre of the city, just over 1 mile from the EICC. All tickets have now sold out for this event. To be added to the waiting list please email [email protected] and we will inform you of any cancellations received.

Annual conference abstractsFollowing the conference, the abstracts approved by the editor will be published in the Clinical and Experimental Allergy Journal.

Chair and speaker previewPlease ensure that you are available in your presentation room at least ten minutes before the start of the session. It is recommended that all speakers visit the speaker preview room to confirm audio-visual requirements at least three hours prior to the start of the session. The speaker preview room is located in the Lomond Foyer and will be open during the following times:Monday 25th April 07:30 – 19:00Tuesday 26th April 07:30 – 19:00Wednesday 27th April 07:30 – 13:00

Poster presentations Posters will be displayed in the Exhibition area in the Strathblane Hall for the duration of the conference. All poster presenters should ensure that they mount their poster beneath the correct poster number, which you will have been notified of before the event. Posters can be mounted on Monday 25th April from 09:00 and should be removed on Wednesday 27th April before 11:00. Posters not removed by this time will be disposed of by the venue. There will be a poster judging session on Tuesday lunchtime from 12:35 - 14:00. All poster presenters (including those selected for oral presentations) must attend and present their poster during this time to poster judges and conference delegates.

13wao-bsaci.org

Speaker’s CornerThis year, we have four ‘Speaker’s Corner’ events taking place in the Cromdale Hall, which is situated alongside the exhibition. Podium discussions will be held by experts in their field and will offer an informal chance for delegates to ask questions and engage in the debate and a chance to interact with speakers and discuss topical issues during the breaks.Speaker’s Corner presentations will take place at the following times:

Monday 25th April 15:35– 16:00 Tuesday 26th April 10:35 – 11:00 Tuesday 26th April 15:40 – 16:00Wednesday 27th April 10:35 – 11:00For more information please see the Programme.

Allergy WorkshopsOnce again we have a workshop session as part of this year’s programme.These informal presentations and discussions will share learning and experience from a range of areas and will take place in the Carrick & Ochil Suites on Level 1.Tuesday 26th April 12:35 - 14:00For more information please see the Programme.

Oral abstract presentationsThe oral abstract presentations will take place on Tuesday 26th April 11:05 - 12:35. Oral abstract presenters must report to the speaker preview room to check their slides at least three hours before their presentation. Please see the programme for the oral abstract session rooms.

Accreditation, Evaluation and Certificate of AttendanceThe WAO & BSACI 2022 UK Conference has been approved by the Royal College of Physicians for 16 CPD credits.Your certificate of attendance will be emailed to you automatically after the event.

EACCME® accreditationThe Joint Conference World Allergy Organization (WAO) and British Society for Allergy & Clinical Immunology (BSACI), Edinburgh, United Kingdom, 25/04/2022-27/04/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 14European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM.


Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.To obtain your certificate, please complete the online feedback survey within two weeks of attending the event.

Industry support disclosureThis event is supported, in part, by funding from Industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support. Appropriate acknowledgement of all supporting organisations is made in the programme guide, on the website and with signage during the event.

CloakroomA staffed cloakroom is located close to the conference registration area.

WiFi

WiFi is available for conference participants throughout the venue. Login details are available at the registration desk.

Security and safety

Please do not leave bags and luggage unattended at any time, whether inside or outside session halls.

Liability and insurance

The conference Secretariat and Organisers cannot accept liability for personal accidents or loss or damage to private property of participants either during or indirectly arising from the WAO & BSACI 2022 UK Conference. Participants are advised to take out their own personal travel and health insurance for their trip.

Conference secretariat

medivents.co.uke: [email protected]

Medivents Ltd, Spirella Building, Bridge RoadLetchworth Garden CityHertfordshire SG6 4ET


LIN

KSTO

STR A

THB

LAN

EH

ALL

STRATHBLAN LLAHE

Tinto

Moor toof

KilsythLOMOND SUITE

ssenisuBrtneC e

LOMOND FOYER

rtA cnartnEmui e

SOUTRA

ATRIUM

Strathblane Entrance

Level 0Entrance and break-out rooms

CAFÉ

LIN

KSTO

GAL

LOW

AYSU

ITE

LAG WOL YA ETIUS

Carrick

sirraHOch

il2

31 2

12

31

1

2 3

DRESSING ROOMSGLADSMUIR ROOM

Level 1Break-out rooms

Venue floor plan

17wao-bsaci.org

PENTLAND

Sidlaw Fintry

Level 3Plenary

CROMDALE HALL

LENNOX SUITE

TURN TABLEACCESS

1 2Lammermuir

1 2 3Moffat

EICCKITCHEN

Bar

DELIVERY BAYS A & B

DELIVERY BAY C

Level -2Exhibition


The safety of delegates is our priority and we have worked with the EICC to ensure we make the conference as safe as possible for everyone.As well as continuing to take precautionary measures including the provision of hand sanitiser and social distancing markers, we would still like to encourage all attendees to wear a face covering in crowded areas where social distancing may not be possible.Face masks will be freely available around the conference venue if required.

We have also taken the below steps to ensure we provide a safe conference for all.l Hand- sanitising stations will be provided around the venue. l The entire venue has been deep cleaned prior to the conference with Kora

Drymist. This cleaning agent will protect from any contamination for up to 30 days in large areas and delivers 24 hours protection on areas that could come into contact with skin.

l The venue ventilation operates at 100% fresh air with no recirculation of air from the conference space.

l The cleaning of the toilets will be increased daily and we are taking measures to reduce queuing at the toilets.

We encourage all attendees to use contactless payments for any catering and the car park.

International travelInternational delegates requiring a departure PCR test can book one here. This PCR test centre is located just 5 minutes from the Edinburgh International Conference Centre.

Safety measures

19wao-bsaci.org

HANDS

FACE

SPACE


Ryaltris Prescribing InformationRyaltris (mometasone furoate and olopatadine hydrochloride) Please refer to the Summary of Product Characteristics (SmPC) before prescribing. One delivered dose contains mometasone furoate monohydrate equivalent to 25 microgram mometasone furoate and olopatadine hydrochloride equivalent to 600 micrograms olopatadine. Indication: treatment of moderate to severe nasal symptoms associated with allergic rhinitis in adults and adolescents 12 years of age and older Posology and method of administration: The usual recommended dose is two actuations in each nostril twice daily (morning and evening). Children below 12 years: Ryaltris is not recommended. Elderly: No dose adjustment required. Renal and hepatic impairment: there are no data in patients with renal and hepatic impairment, however no dose adjustment is expected to be required. Contraindications: Hypersensitivity to the active substances or to any of the excipients. Ryaltris should not be used in the presence of untreated localised infection involving the nasal mucosa, such as herpes simplex. Patients who have experienced recent nasal surgery or trauma should not use a nasal corticosteroid until healing has occurred. Precautions: Local nasal effects: nasal ulceration and nasal septal perforation have been reported in patients following intranasal antihistamines. Nasal septal perforation has been reported following intranasal corticosteroids. Patients using Ryaltris over several months or longer should be examined periodically for possible changes in the nasal mucosa. Ryaltris is not recommended in cases of nasal septum perforation. In clinical studies with mometasone furoate administered intranasally, the development of localised infections of the nose and pharynx with Candida albicans has occurred; may require treatment and discontinuation of Ryaltris. Patients using Ryaltris over several months or longer should be examined periodically for evidence of Candida infection or other signs of adverse effects on the nasal mucosa. Visual disturbancesmay be reported with systemic and topical corticosteroid use. Symptoms such as blurred vision or other visual disturbances should be considered for ophthalmologist referral for evaluation of possible causes including cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR). Hypersensitivity Reactions including instances of wheezing, may occur. Discontinue Ryaltris if such reactions occur. Immunosuppression: Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible patients and those using corticosteroids. In children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculous infections of the respiratory tract, untreated local or systemic fungal or bacterial infections, systemic viral or parasitic infections, or ocular herpes simplex because of the potential for worsening of these infections. Systemic Effects of Corticosteroids: potential systemic effects may include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). When intranasal steroids are used at higher than recommended dosages or in susceptible individuals at recommended dosages, systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear. If such changes occur, the dosage of Ryaltris should be discontinued slowly, consistent with accepted procedures for discontinuing oral corticosteroid therapy. The concomitant use of intranasal corticosteroids with other inhaled corticosteroids could increase the risk of signs or symptoms of hypercorticism and/or suppression of the HPA axis. If there is evidence for higher than recommended

doses being used, then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery. The replacement of a systemic corticosteroid with a topical corticosteroid can be accompanied by signs of adrenal insufficiency, and some patients may experience symptoms of withdrawal. Patients previously treated for prolonged periods with systemic corticosteroids and transferred to topical corticosteroids should be carefully monitored for acute adrenal insufficiency in response to stress. In those patients who have asthma or other clinical conditions requiring long term systemic corticosteroid treatment, too rapid a decrease in systemic corticosteroids may cause a severe exacerbation of their symptoms. Somnolence: in isolated cases dizziness, lethargy, fatigue and somnolence may occur when using Ryaltris. In these cases, the ability to drive and use machines may be impaired. Alcohol and other CNS depressants may enhance this effect. Antihistamine effects:concomitant use of other antihistaminic drugs administered may increase the risk of antihistamine adverse effects. Paediatric population: It is recommended that the height of children receiving prolonged treatment with nasal corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of nasal corticosteroid if possible, to the lowest dose at which effective control of symptoms is maintained. Excipients: Ryaltris contains 0.02 mg benzalkonium chloride in each actuation. Benzalkonium chloride may cause irritation or swelling inside the nose, especially if used for a long time. Adverse reactions: Common (≥1/100 to <1/10): dysgeusia (unpleasant taste), epistaxis, nasal discomfort. Uncommon (≥1/1,000 to <1/100): dizziness, headaches, somnolence, nasal dryness, dry mouth, abdominal pain, nausea, fatigue. Rare (≥1/10,000 to <1/1000) bacterial vaginosis, anxiety, depression, insomnia, lethargy, migraine, blurred vision, dry eye, eye discomfort, ear pain, nasal inflammation, nasal mucosal disorder, oropharyngeal pain, sneezing, throat irritation, constipation, sore tongue, laceration. Incidence not known (reported from use of corticosteroids): pharyngitis, upper respiratory tract infection, hypersensitivity including anaphylactic reactions, angioedema, bronchospasm, and dyspnoea, cataracts, glaucoma, increased intraocular pressure, nasal septum perforation. Marketing authorisation number: PL 25258/0331 Marketing Authorisation Holder and distributer: Glenmark Pharmaceuticals Europe Limited, Laxmi House, 2B Draycott Avenue Kenton, Middlesex, HA3 0BU. United Kingdom Legal classification: POM Cost:£13.32. 1 bottle with 29 g suspension (240 actuations) Date of preparation: June 2021. Job number: PP-UK-RYAL-0001

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should

also be reported to Glenmark Pharmaceuticals Europe Ltd [email protected] or call 0800 458 0383

Scan to visit www.ryaltris.co.uk

Ryaltris® combination intranasal spray works within minutes and lasts for 24 hours with twice-daily dosing2

Find out more at www.ryaltris.co.uk

Ryaltris® opens up more than just airways1,2

Ryaltris® is indicated in adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis (AR).1

Live like you

References: 1. Ryaltris® Summary of Product Characteristics. 2. Gross GN, et al. Ann Allergy Asthma Immunol 2019;122:630–638.Ryaltris® is a registered trademark of Glenmark Speciality S.A.© 2022 Glenmark Pharmaceuticals Europe Ltd. All rights reserved.Date of preparation: March 2022 PP-UK-RYAL-0106

018272_AW_Ryaltris_LADY_SAR_WAO_BSACI_Ad_DIGITAL_A4.indd 1 16/03/2022 14:44

WAO & BSACI 2022 UK Conference

Welcome ReceptionPlease join us for the Welcome Reception on

Monday 25th April This event will take place from: 18:45 – 19:45

In the: Strathblane Hall, EICCTickets cost £15 and are available from the registration desk (limited availability)

Presidents’ Dinner Please join us for the Presidents’ Dinner

Tuesday 26th April This event will take place from: 20:30 – 23:00

at the: Royal College of SurgeonsAll tickets have now sold out for this event.To be added to the waiting list please email

[email protected] and we will inform you of any cancellations received.

Ryaltris Prescribing InformationRyaltris (mometasone furoate and olopatadine hydrochloride) Please refer to the Summary of Product Characteristics (SmPC) before prescribing. One delivered dose contains mometasone furoate monohydrate equivalent to 25 microgram mometasone furoate and olopatadine hydrochloride equivalent to 600 micrograms olopatadine. Indication: treatment of moderate to severe nasal symptoms associated with allergic rhinitis in adults and adolescents 12 years of age and older Posology and method of administration: The usual recommended dose is two actuations in each nostril twice daily (morning and evening). Children below 12 years: Ryaltris is not recommended. Elderly: No dose adjustment required. Renal and hepatic impairment: there are no data in patients with renal and hepatic impairment, however no dose adjustment is expected to be required. Contraindications: Hypersensitivity to the active substances or to any of the excipients. Ryaltris should not be used in the presence of untreated localised infection involving the nasal mucosa, such as herpes simplex. Patients who have experienced recent nasal surgery or trauma should not use a nasal corticosteroid until healing has occurred. Precautions: Local nasal effects: nasal ulceration and nasal septal perforation have been reported in patients following intranasal antihistamines. Nasal septal perforation has been reported following intranasal corticosteroids. Patients using Ryaltris over several months or longer should be examined periodically for possible changes in the nasal mucosa. Ryaltris is not recommended in cases of nasal septum perforation. In clinical studies with mometasone furoate administered intranasally, the development of localised infections of the nose and pharynx with Candida albicans has occurred; may require treatment and discontinuation of Ryaltris. Patients using Ryaltris over several months or longer should be examined periodically for evidence of Candida infection or other signs of adverse effects on the nasal mucosa. Visual disturbancesmay be reported with systemic and topical corticosteroid use. Symptoms such as blurred vision or other visual disturbances should be considered for ophthalmologist referral for evaluation of possible causes including cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR). Hypersensitivity Reactions including instances of wheezing, may occur. Discontinue Ryaltris if such reactions occur. Immunosuppression: Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible patients and those using corticosteroids. In children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculous infections of the respiratory tract, untreated local or systemic fungal or bacterial infections, systemic viral or parasitic infections, or ocular herpes simplex because of the potential for worsening of these infections. Systemic Effects of Corticosteroids: potential systemic effects may include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). When intranasal steroids are used at higher than recommended dosages or in susceptible individuals at recommended dosages, systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear. If such changes occur, the dosage of Ryaltris should be discontinued slowly, consistent with accepted procedures for discontinuing oral corticosteroid therapy. The concomitant use of intranasal corticosteroids with other inhaled corticosteroids could increase the risk of signs or symptoms of hypercorticism and/or suppression of the HPA axis. If there is evidence for higher than recommended

doses being used, then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery. The replacement of a systemic corticosteroid with a topical corticosteroid can be accompanied by signs of adrenal insufficiency, and some patients may experience symptoms of withdrawal. Patients previously treated for prolonged periods with systemic corticosteroids and transferred to topical corticosteroids should be carefully monitored for acute adrenal insufficiency in response to stress. In those patients who have asthma or other clinical conditions requiring long term systemic corticosteroid treatment, too rapid a decrease in systemic corticosteroids may cause a severe exacerbation of their symptoms. Somnolence: in isolated cases dizziness, lethargy, fatigue and somnolence may occur when using Ryaltris. In these cases, the ability to drive and use machines may be impaired. Alcohol and other CNS depressants may enhance this effect. Antihistamine effects:concomitant use of other antihistaminic drugs administered may increase the risk of antihistamine adverse effects. Paediatric population: It is recommended that the height of children receiving prolonged treatment with nasal corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of nasal corticosteroid if possible, to the lowest dose at which effective control of symptoms is maintained. Excipients: Ryaltris contains 0.02 mg benzalkonium chloride in each actuation. Benzalkonium chloride may cause irritation or swelling inside the nose, especially if used for a long time. Adverse reactions: Common (≥1/100 to <1/10): dysgeusia (unpleasant taste), epistaxis, nasal discomfort. Uncommon (≥1/1,000 to <1/100): dizziness, headaches, somnolence, nasal dryness, dry mouth, abdominal pain, nausea, fatigue. Rare (≥1/10,000 to <1/1000) bacterial vaginosis, anxiety, depression, insomnia, lethargy, migraine, blurred vision, dry eye, eye discomfort, ear pain, nasal inflammation, nasal mucosal disorder, oropharyngeal pain, sneezing, throat irritation, constipation, sore tongue, laceration. Incidence not known (reported from use of corticosteroids): pharyngitis, upper respiratory tract infection, hypersensitivity including anaphylactic reactions, angioedema, bronchospasm, and dyspnoea, cataracts, glaucoma, increased intraocular pressure, nasal septum perforation. Marketing authorisation number: PL 25258/0331 Marketing Authorisation Holder and distributer: Glenmark Pharmaceuticals Europe Limited, Laxmi House, 2B Draycott Avenue Kenton, Middlesex, HA3 0BU. United Kingdom Legal classification: POM Cost:£13.32. 1 bottle with 29 g suspension (240 actuations) Date of preparation: June 2021. Job number: PP-UK-RYAL-0001

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should

also be reported to Glenmark Pharmaceuticals Europe Ltd [email protected] or call 0800 458 0383

Scan to visit www.ryaltris.co.uk

Ryaltris® combination intranasal spray works within minutes and lasts for 24 hours with twice-daily dosing2

Find out more at www.ryaltris.co.uk

Ryaltris® opens up more than just airways1,2

Ryaltris® is indicated in adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis (AR).1

Live like you

References: 1. Ryaltris® Summary of Product Characteristics. 2. Gross GN, et al. Ann Allergy Asthma Immunol 2019;122:630–638.Ryaltris® is a registered trademark of Glenmark Speciality S.A.© 2022 Glenmark Pharmaceuticals Europe Ltd. All rights reserved.Date of preparation: March 2022 PP-UK-RYAL-0106

018272_AW_Ryaltris_LADY_SAR_WAO_BSACI_Ad_DIGITAL_A4.indd 1 16/03/2022 14:44

��

��


Programme - Day 1Monday 25th April 2022

25wao-bsaci.org

Day 1 Monday 25th April 2022

09:00Registration opens

09:00 – 10:00 Welcome coffee Cromdale Hall L-2

10:00 – 11:30 Global allergyPentland Sidlaw Auditorium L3Chairs: José Antonio Ortega-Martell, Mexico and Philip W. Rouadi, LebanonGlobal trends in the epidemiology of food allergyHugh Sampson, USA

Impact of globalisation in the management of anaphylaxisLuciana Kase Tanno, France

Challenges in managing allergies and asthma in LMICs. Thinking forward! Mamidipudi Thirumala Krishna, UK

11:35 – 12:35 Allergy & the environmentPentland Sidlaw Auditorium L3Chairs: Michael Levin, South Africa and Louise Michaelis, UKAeroallergens around the globe. Temperate vs Tropic climatesLuis Caraballo, Colombia

Indoor air pollution and effects on Allergic DiseaseJames L. Sublett, USA

Biologics Moorfoot Kilsyth Suite L0Chairs: Jonathan Bernstein, USA and Nikos Papadopoulos, GreeceThe biologics era: Brave new world or incremental improvement in therapy?Bryan Martin, USA

Can biomarkers help us prescribe and monitor biologic therapy?Thomas B. Casale, USA

12:35 – 14:00 Lunch - Cromdale Hall L-2Poster viewing - Strathblane Hall L0

12:45 – 13:45 Industry sessionsee page 98 for detailsMoorfoot Kilsyth Suite L0

12:45 - 13:45 Listening to patients and improving their lives Pentland Sidlaw Auditorium L3Chairs: Chris Corrigan, UK and Christina Jones, UK Anaphylaxis Campaign Learning from Prevention of Future Deaths reportsSimon Williams and Melissa Singh, UK Allergy UKReal life data: why It’s time to take allergy seriouslyAmena Warner, UKNatasha Allergy Research Foundation (NARF) Making Allergy History. Beyond Natasha’s Law to eradicating allergy – our research funding priorities Nadim Ednan-Laperouse and Tanya Ednan-Laperouse, and Tim McLachlan, UK


15:30 – 16:00 Tea/coffee - Cromdale Hall L-2Poster viewing - Strathblane Hall L0

15:35 – 16:00 Speaker's corner sessionCromdale Hall L-2Chair: Rebecca Batt, UKThe nurse’s role. International similarities and differencesJenny Adison, UK and Maria Crain, USA

16:05 – 17:35 Presidents' welcome keynote lectures Pentland Sidlaw Auditorium L3Chairs: George Gkimpas, UK and Bryan Martin, USAA comprehensive approach to managing food allergyGraham Roberts, UKOral and sublingual immunotherapy for food allergyMotohiro Ebisawa, Japan Viral infections and allergy interactions in the post-COVID eraNikolaos Papadopoulos, Greece

17:45 – 18:45 Industry Session see page 98 for details Moorfoot Kilsyth Suite L0

18:45 - 19:45 Welcome Reception Strathblane Hall L0

Day 1 continued

14:00 – 15:30 COVID-19 Pentland Auditorium L3Chairs: Thomas Casale, USA and Yoon-Seok Chang, South KoreaChallenges in tackling ethnicity-related risks in the COVID pandemicManish Pareek, UKTH2 responses in COVID-19 infectionJohn Warner, UK COVID-19 infection: zero tolerance or to live with it?Gary Wong, Hong Kong

Preventing Allergy Sidlaw Auditorium L3Chairs: Olympia Tsilochristou, UK and Leanne Goh, UKB and Treg cells and induction of tolerance Mübeccel Akdis, Switzerland Interventions based on "Epithelial Barrier Hypothesis" for the prevention of allergic disease Cezmi Akdis, SwitzerlandMicrobiome: the gut/skin axis in allergy prevention Liam O’ Mahony, Ireland

JOINT SESSION WITH EAACIUpper respiratory system Moorfoot Kilsyth Suite L0Chairs: Jürgen Schwarze, UK and Ioanna Agache, Romania Endotypes of CRSwNPSanna Toppila-Salmi, FinlandOlfaction and immunity, the nose as interfacePeter Valentin Tomazic, AustriaNon-allergic rhinitisValerie Hox, Belgium

27wao-bsaci.org

Programme - Day 2Tuesday 26th April 2022


Allergy managementSidlaw Auditorium L3Chairs: Andrew Williams, UK and Deborah Marriage, UKHow to manage anaphylaxis in primary care Yoon-Seok Chang, Republic of Korea

Global Impact of the DRACMA guidelines. Time for an update? Alessandro Fiocchi, Vatican City Psychological interventions for patients with allergy: what do patients say they need? Christina Jones, UK

10:35 – 11:00 Speaker's corner session Cromdale Hall L-2Chair: Lucy Common, UKPutting the person into the personalised asthma action planRebecca Batt, UK


11:05 – 12:35 Oral abstracts sessions Primary care & Allied healthMoorfoot Kilsyth Suite L0Chair: Matt Doyle, UKO01 Improvements in quality of life and food neophobia scores in adults after peanut oral immunotherapyHannah Hunter, UK

O02 Preliminary findings for the effect of group cognitive behavioural therapy in parents, adults and children with food allergyHolly Tallentire, UK

Day 2 Tuesday 26th April 2022

09:00 – 10:30 Immunotherapy Pentland Auditorium L3Chairs: James Gardner, UK and Hugh Sampson, USANovel approaches: allergen modification/delivery plus passive immunotherapy without allergens Stephen Durham, UK

Allergen ‘plus’ approaches for immunotherapyThomas B. Casale, USA

SLIT as mainstream management for seasonal and perennial allergiesAdam Fox, UK

Drug allergyMoorfoot Kilsyth Suite L0Chairs: Mübeccel Akdis, Switzerland and Shuayb Elkhalifa, UK Allergic reactions to COVID vaccines: much ado about nothing? Paul Turner, UK

Biologics: Mechanisms and Hypersensitivity Luciana Kase Tanno, France

Outcomes and safety of rapid desensitization Mariana Castells, USA

29wao-bsaci.org

O04 Caregivers’ experiences of accessing mental health services for food allergy related distress: Data from the GAPS studyRebecca Knibb, UK

O05 Impact of community dietetic leadership in paediatric food allergy on the burden of care for both primary care and families: A service evaluation comparisonLisa Waddell, UK

O06 Prevalence and pattern of milk allergy overdiagnosis in the BEEP trial populationEmilia Jackson, UK

Allergy educationHarris Suite 2 L1Chair: Karen Wright, UKO07 Guideline translation: a novel approachDermot Ryan, UK

O08 Early childhood allergy prevention by parents: results from a multicentre assessment of health literacy-related knowledge, practices and decision-makingJonas Lander, Germany

O09 Food matters: A multidisciplinary initiative raising food allergy awareness and safety on a paediatric wardMinal Gandhi, UK

O10 Primary care facilities improved by multifaceted training interventions using blended learning and site visits.Michael Levin, South Africa

O11 Going green “From paper to QR code”: A quality improvement project to develop paperless allergy patient information in the time of CovidLisbeth Cyriac, UK

Day 2 continued

O12 Teaching children with food allergy to manage anaphylaxis: caregivers’ perspectivesJuan E. Trujillo Wurttele, Ireland

Paediatric clinicalPentland Auditorium L3Chair: Jürgen Schwarze, UKO13 Early initiation of short term moisturization from birth significantly decreases the rate of AD at 12 months in a high-risk cohort.Dhanis Lad, Ireland

O14 Efficacy of Dupilumab in Quadrants of Elevated- vs Low- Type 2 Biomarkers in Children with Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGERoss Thomas, UK

O15 Trajectories of restrictive pattern of lung function FEV1/FVC to physiological peak and their relationship with early life risk-factors and cardiac markersMatea Deliu, UK

O16 Continued Safety of Peanut (Arachis hypogaea) Allergen Powder-dnfp in Children and Teenagers with Peanut Allergy: Pooled Analysis From Controlled and Open-Label Phase 3 TrialsJonathan O’B Hourihane, Ireland

O17 Evolution of eczema, wheeze and rhinitis from infancy to early adulthood: analysis of four birth cohort studiesSadia Haider, UK

O18 An international Delphi consensus study on the detection and management of milk allergyHilary Allen, UK



Adult clinicalSidlaw Auditorium L3Chair: Gunter Sturm, AustriaO19 Safety evaluation of two recently described delabeling algorithms for unexplored beta-lactam drug hypersensitivity reactionsIleana-Maria Ghiordanescu, RomaniaO20 Efficacy and Safety of Upadacitinib vs Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Four Body Regions - Analysis from the Heads Up StudyJacob P. Thyssen, DenmarkO21 COVID vaccine allergy; the experience of a UK allergy serviceCiara Glass, UKO23 Overview of Asthma Patients Followed Up in a Tertiary ClinicDilsad Mungan, TurkeyO24 Childhood physical abuse is associated with asthma in adult age: Results from a population-based studyKatharina Piontek, GermanyBasic scienceHarris Suite 1 L1Chair: Stephen Durham, UKO25 Mechanisms of Immune Response and Relationship to Clinical Reactivity During Oral Immunotherapy With Peanut (Arachis hypogaea) Allergen Powder-dnfp: Findings From the Phase 3 PALISADE TrialErik Wambre, USA

O26 Using machine learning approaches for analysis of data collected in a birch pollen AIT trialLorenz Aglas, Austria

O27 Tryptase release does not discriminate between IgE- and MRGPRX2-mediated mast cell degranulationJessy Elst, BelgiumO28 Shrimp Skin Prick Test extracts show critical variability in full allergen repertoireThimo Ruethers, SingaporeO29 A novel virus-like particle for the treatment of cat allergyMatthew D Heath, UKO30 NTLA-2002: CRISPR-Mediated Gene Knockout of KLKB1 as a Potential Single-Dose Treatment for Hereditary Angioedema (HAE) Hilary Longhurst, New Zealand

12:35 – 14:00 Lunch - Cromdale Hall L-2Poster Judging - Strathblane Hall L0

12:35 – 14:00 WorkshopsCarrick and Ochil Suites L1Skin prick and intradermal testingLucy Common, UKPhysical urticaria testsClive Grattan, UKNovel health appsJames Gardner, UKEmollient, steroid and other eczema creams and their useKelly Parker, UK

Nasal aspirin challenge and desensitisationKathryn Haworth, UK

Immunotherapy in practiceKatherine Knight, UK

31wao-bsaci.org

Day 2 continued

12:45 – 13:45 Industry Sessionsee page 99 for details Moorfoot Kilsyth Suite L0

14:05 – 15:35 Food allergy Pentland Auditorium L3Chairs: Isabel Skypala, UK and Hasan Arshad, UKToo high, too low: improving precautionary allergen labelling across the globePaul Turner, UKNon-plant derived pan-allergensRonald van Ree, The Netherlands Bringing the next generation of food allergy tests into the allergy clinicAlexandra Santos, UK Respiratory allergyMoorfoot Kilsyth Suite L0Chairs: Mário Morais-Almeida, Portugal and Angela Simpson, UKMachine learning in asthma: from endotype discovery to clinical practice Adnan Custovic, UK

Biologic management of asthma and asthma-COPD overlap (ACOS) Anahi Yáñez, ArgentinaAdvances in occupational disorders in the new decade David Peden, USA

JOINT SESSION WITH AAAAIInborn Errors of Immunity (IEI) Sidlaw Auditorium L3

Chairs: John Warner, UK and Giselle Mosnaim, USA

The crossroad between atopic disease and IEIJoshua Milner, USA Current status of immune reconstitution for IEIAndrew Gennery, UK

Optimal application of next generation sequencing in the evaluation of a patient with likely IEIRoshini Abraham, USA


15:40 – 16:00 Speaker's corner sessionCromdale Hall L-2Chair: Isabel Skypala, UKPrevention in practice – what do we tell parents about weaning, early introduction of food and dietary diversity? Kate Grimshaw, UK

16:05 – 17:35 Mast Cell Disease Moorfoot Kilsyth Suite L0Chairs: Clive Grattan, UK and Ariharan Anatharachagan, UKDiagnostic criteria and classification of mast cell disordersPatrizia Bonadonna, ItalyNovel biologic treatments for chronic urticariaJonathan Bernstein, USAComorbidity patterns in urticariaSandra N. González-Díaz, Mexico



Allergy impact Sidlaw Auditorium L3Chairs: Nick Makwana, UK and Matthew Doyle, UKFrom feeding difficulties to ARFID – Practical tools for healthcare professionals Rosan Meyer, UKNutritional challenges in food allergy Isabel Skypala, UKImpact of food allergy on the quality of life in the UK: The Foodsensitive study Rebecca Knibb, UK

Celebrating excellence in allergy care and research Pentland Auditorium L3Chair: Graham Roberts, UKJack Pepys Lecture - "Epithelial Barrier Hypothesis" for the development of allergic and autoimmune diseasesCezmi Akdis, SwitzerlandBarry Kay awardsWilliam Frankland awardPaul Turner, UK The Harry Morrow Brown lectureAndrew Clark, UK

17:45 - 18:45 GA2LEN ANACare: 2022 clinical practice guidelines for food allergy management Moorfoot Kilsyth Suite L0Chair: Graham Roberts, UK Introducing GA2LEN VideoTorsten Zuberbier, GermanyAllergen immunotherapy and biologicals Antonella Muraro, ItalyDietary interventions Susanne Halken, Denmark

Risk of reactions and education Paul Turner, UK

20:30 – 23:00 Presidents’ dinner

L-2 - Level-2

L0 - Level 0

L1 - Level 1

L3 - Level 3

See pages 16 & 17 for the venue floor plan

33wao-bsaci.org

Programme - Day 3Wednesday 27th April 2022


09:00 – 10:30 Hot off the press Pentland Auditorium L3Chairs: Adnan Custovic, UK and Chris Corrigan, UK

BSACI 2021 egg allergy guidelines Susan Leech, UK

EAACI 2021 anaphylaxis guidelinesVictòria Cardona, Spain

GINA 2021 reportLouise Fleming, UK

Global allergy Moorfoot Kilsyth Suite L0Chairs: Isabel Skypala, UK and Sandra N. González-Díaz, Mexico

Latex allergy update: new insights into a global problem Ignacio J. Ansotegui, Spain

Shellfish allergy update: A world viewAndreas Lopata, Australia

Hymenoptera venom allergy update: A global perspectiveProfessor Gunter Sturm, Austria

Joint society Session with JSA Atopic Dermatitis Sidlaw Auditorium L3Chairs: Motohiro Ebisawa, Japan and Cezmi Akdis, Switzerland Epidermal barrier formation Hiroshi Kawasaki, Japan

Immunological barrier in atopic dermatitisKenji Kabashima, Japan

Susceptibility and risk factor of food allergy and atopic dermatitisKiwako Yamamoto-Hanada, Japan


10:35 – 11:00 Speaker's corner session Cromdale Hall L-2Allergy education: Exploring useful cases for teaching allergy Louise Michaelis and Karen Wright, UK

11:05 – 12:05 Keynote Lectures: environmental exposures Pentland Sidlaw Auditorium L3Chairs: Graham Roberts, UK and Motohiro Ebisawa, Japan

Allergy, pollution and climate issuesStephen Holgate, UK

Allergy, helminths and viruses Jürgen Schwarze, UK

12:05 – 13:35The Joined WAO, BSACI, EAACI, AAAAI & JSA Year in Review Pentland Sidlaw Auditorium L3Chairs: Vibha Sharma, BSACI, Motohiro Ebisawa, JSA and Giselle Mosnaim, AAAAI

Biologics Bryan Martin, WAO

Anaphylaxis Mário Morais Almeida, WAO

Immunotherapy Marek Jutel, EAACI

Papers that should change your clinical practice? Graham Roberts, BSACI

Conference Close

Day 3 Wednesday 27th April 2022

35wao-bsaci.org

Day 1 Monday 25th April 202209:00 – 10:00BRIT Registry Meeting Carrick Suite L1 18:45 – 19:15Nurses social event Strathblane Hall L0

Day 2 Tuesday 26th April 202208:00 – 09:00Paediatric Open Meeting Carrick Suite Primary Care Committee Ochil Suite L119:00 – 20:00Trainees Meeting Carrick Suite L1Dietitians Meeting Moorfoot Kilsyth Suite L0Adult Allergy Group Sidlaw Auditorium L3

Speciality Group Meetings


Poster Abstracts

37wao-bsaci.org

Adult Clinical

P002 Incidence of perioperative hypersensitivity reactions: A single-center, prospective, cohort experience in the United StatesAlexei Gonzalez-Estrada, USA

P003 Long-term efficacy of dupilumab in patients with asthma with and without comorbid chronic rhinosinusitis/nasal polyposis Ross Thomas, UK

P004 Evolution of house dust mite allergy control during treatment with the SQ HDMsublingual immunotherapy (SLIT)-tablet in real-life clinical practice - CARIOCA:french non-interventional study Antoine Chartier, France

P005 ACE-inhibitors related angioedema: an Italian casuistry Antonio Cocchiario, Italy

P006 Gadolinium contrast-based agents: use in real-life conditions after negative allergy work-up by skin testing Audrey Kamga, France

P007 Hypereosinophilia of undetermined significance in a Rheumatoid Arthritis Patient Betul Dumanoglu, Turkey

P008 Patients' experience and treatment effectiveness after receiving allergen immunotherapy - a real world experience Ching Ching Yung, UK

P009 Systemic Contact Dermatitis Due to Iodinated Contrast Media Dasha Roa, UK

P010 Dupilumab efficacy in LIBERTY ASTHMA QUEST patients with uncontrolled, moderate-to-severe asthma by allergen sensitization status Ross Thomas, UK

P012 Chronic spontaneous urticaria and parasitosis Gayathri Baiju, UK

P013 Multiple sensitisation to Pathogenesis related-10 protein resulting in systemic reaction Alla Nakonechna, UK

P014 Assessing the content validity of three asthma-specific quality of life questionnaires among severe asthma patients in Singapore Helen E. Smith, Singapore

P015 Optimal tests for predicting the outcome of oral food challenges to hazelnut, walnut and cashew in clinical practice Helena Rey Garcia, UK


P016 Sensitivity of drug provocation test (DPT) for patients with suspected nonsteroidal anti-inflammatory drugs (NSAIDs) hypersensitivity reclassified, calculated in a population from a large database Ileana-Maria Ghiordanescu, Romania

P018 The influence of maternal respiratory allergy on obstetrics and perinatal outcomesIrene Bartha, UK

P019 The influence of air pollution on preterm delivery and low birth weight in women with or without respiratory allergyIrene Bartha, UK

P020 Single Center Experience of Allergological Evaluation for Suspected Steroid Hypersensitivity in Adults Jackie Moor, UK

P021 Continued implementation of changes in delivery of Allergy & Immunology services introduced during COVID-19 pandemic Jackie Moor, Uk

P022 Tolerance of ofatumumab in a patient with SLE with previous infusion reactions with rituximab, and IgG anti-rituximab antibodies John Guly, UK

P025 Characterization of Hematologic and Transaminase Laboratory Findings Associated With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Results of Two Phase 3 Trials (Measure Up 1 and 2) Jonathan I. Silverberg, USA

P026 True IgE-mediated allergy to Covid-19 vaccines is rare: an audit of outcomes in a ‘high-risk’ cohort Jonathan Watt, UK

P027 Subcutaneous immunotherapy study demonstrates clinically relevant improvement in primary field outcome in grass pollen allergic subjects Kemi Oluwayi, UK

P028 Case report: immediate hypersensitivity to chloroxylenol and chlorocresol Kostadin Stoenchev, UK

P029 A Quality Improvement Project on Improving the Classification of Drug-Related Hypersensitivity Reactions in Allergy Clinic at Homerton University Hospital Ky Lyn Tan, UK

P031 AGEP induced by codeine confirmed by patch testing, without cross-reactivity to other opioidsMaria Prasinou, UK

P032 TARGET – Long-term benefits of MCT®-associated allergoid SCIT on allergic rhinitis and asthma under real life conditions Matthias F. Kramer, UK

39wao-bsaci.org

P033 Starting as cold-induced anaphylaxis but following as urticaria Merve Poyraz, Turkey

P034 Sustained Long-Term Dupilumab Efficacy in Adult Patients With Moderate-to-Severe Atopic Dermatitis Transitioning From Weekly Dosing to Every Other Week: Results From an Open-Label Extension Trial Michael J. Cork, UK

P035 Allergist role in reducing vaccine hesitancy Mihaela Zidarn, Slovenia

P036 Patient and public perspectives toward penicillin allergy testing in Manchester, UK Miriam Bennett, UK

P037 Features of laboratory tests in Vietnamese patients with chronic urticaria Nhi Le Thi Kieu, Vietnam

P038 Allergen Immunotherapy: Clinical outcomes data from a real-world clinical practice Pedro Silva, Portugal

P039 Longterm use of nasal powder methyl-cellulose as add-on treatment of chronic rhinosinuitis in asthmatics protects against viral exacerbations Peter Josling, UK

P040 Achieving a Deep Response on Patient-Reported Outcomes with Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Results From Three Phase 3 Trials Raj Chovatiya, USA

P041 Developing a Logo Therapy Focused Program for Individual with Common Variable Immunodeficiency Disease (CVID): Efficacy on Resilience and Quality of Life Ramin Ghasemi Darestani, Iran, Islamic Republic of

P042 An Interpretative Phenomenological Analysis of the Development and Maintenance of Gluten-Related Distress and Unhelpful Eating and Lifestyle Patterns in Coeliac Disease Rose-Marie Satherley, UK

P043 A local clinical audit on the assessment to confirm an anaphylaxis episode in people aged 16 years old and above in an acute hospital settingSara Elhadari, UK

P045 Evaluation of first dose home self-administration of Oralvac sublingual immunotherapy for allergic rhinitis in a UK Allergy centre Soha Khaled Amar, UK

P046 Study Of Efficacy Of SubLingual Immunotherapy (SLIT) In Cases Of Severe Persistent Allergic Rhinitis Subir Jain, India


P047 Smart Trick Of The Trade - " FEEL DEEP [FD]” to ensure 100% Results in Modified Skin Prick Test MethodSubir Jain, India

P048 Allergens exposure and natural immunotherapy Syed Arham Husain, India

P049 Delayed-type hypersensitivity to St John’s Wort confirmed by patch testing: A Case Report Thomas O'Hagan, UK

P050 IgE-Mediated systemic anaphylaxis and its association with gene polymorphisms of ACE, Angiotensinogen, renin, chymase and the angiotensin-1 receptorVeronica Varney, UK

Adult Clinical Oral + Poster Abstracts O19 Safety evaluation of two recently described delabeling algorithms for unexplored beta-lactam drug hypersensitivity reactions Ileana-Maria Ghiordanescu, Romania

O20 Efficacy and Safety of Upadacitinib vs Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Four Body Regions - Analysis from the Heads Up Study Jacob P. Thyssen, Denmark

O21 COVID vaccine allergy; the experience of a UK allergy service Ciara Glass, UK

O23 Overview of Asthma Patients Followed Up in a Tertiary Clinic Dilsad Mungan, Turkey

O24 Childhood physical abuse is associated with asthma in adult age: Results from a population-based study Katharina Piontek, Germany

41wao-bsaci.org

Allergy Education

P051 Evaluation of Patient information leaflet in Pre-school Wheeze - A template for consistency? Anzad Amanullah, UK

P052 The effect of covid-19 and telemedicine on caregiver education: What do caregivers know about anaphylaxis management and have they received adequate training? Caoimhe Cronin, Ireland

P053 Prognostic value of microcirculation in the formation of asthma in children Dmitriy Bondarenko, Russian Federation

P054 Use of relievers in patients with severe asthma on biologics after an educational intervention Mariana Paula Rezelj, Slovenia

P055 Results of a pilot study of the self-assessed knowledge and confidence in managing allergic disorders amongst paediatriciansMartha Cabrera, Spain

P056 Tropomyosin-negative crustacean-allergic grasshopper anaphylaxis Nadia Bitar, UK

P057 “Complacency could lead to a fatality.” A survey of school preparedness for anaphylaxis across West of Scotland Rebecca Totterdell, UK

P058 BSACI Registry coverage of immunotherapy centres across the UK Tom Dawson, UK

Allergy Education Oral + Poster AbstractsO07 Guideline translation: a novel approachDermot Ryan, UK

O08 Early childhood allergy prevention by parents: results from a multicentre assessment of health literacy-related knowledge, practices and decision-makingJonas Lander, Germany

O09 Food matters: A multidisciplinary initiative raising food allergy awareness and safety on a paediatric wardMinal Gandhi, UK

O10 Primary care facilities improved by multifaceted training interventions using blended learning and site visits. Michael Levin, South Africa

O11 Going green “From paper to QR code”: A quality improvement project to develop paperless allergy patient information in the time of CovidLisbeth Cyriac, UK


O12 Teaching children with food allergy to manage anaphylaxis: caregivers’ perspectivesJuan E. Trujillo Wurttele, Ireland

Allied Health

P059 Lifting the lid on adult allergic eye disease, the burden of allergic conjunctivitis and real life experience from Allergy UK’s dataAmena Warner, UK

P060 Economic burden of drug-induced anaphylaxis: what can we do better? Bárbara Kong-Cardoso, Portugal

P061 Association of epidermal differentiation complex genetic variants with house dust mite sensitization in atopic dermatitis patients.: a case control study from kashmiri population(north india) Roohi Rasool, India

P062 Rapid access dietetic-led cow’s milk protein allergy service in East Devon Rosanna Hill, UK

Allied Health Oral + Poster AbstractsO01 Improvements in quality of life and food neophobia scores in adults after peanut oral immunotherapyHannah Hunter, UK

O02 Preliminary findings for the effect of group cognitive behavioural therapy in parents, adults and children with food allergyHolly Tallentire, UK

O03 Dietitians’ perceptions of the benefits and limitations of telehealth in the management of infants with non IgE mediated cow’s milk protein allergy Lydia Collins-Hussey, UK

O04 Caregivers’ experiences of accessing mental health services for food allergy related distress: Data from the GAPS studyRebecca Knibb, UK

Basic Science

P064 In vitro human nasal epithelium model establishment to study histamine effect and fexofenadine benefit as inverse agonist Anne Barbot, France

P065 Understanding the association of polymorphisms in HLA-DQ and IL13 genes with shrimp allergyamong West Bengal population, India Arghya Laha, India

P067 The impact of type 2 diabetes on immunosenescence and functional immunity Edward Lau, United Kingdom

43wao-bsaci.org

P070 Is Omalizumab a potential IFN-α inducer in SARS-CoV-2 infection? Laura Cozzi, Italy

P072 Fungal allergic sensitization in young rural Zimbabwean children: gut mycobiome and seroreactivity characteristics Lorraine Pfavayi, United Kingdom

P073 Association between air pollution levels and drug sales for allergies in 63 million people in metropolitan France in 2013Marwan El Homsi, France

P074 Vaccination against peanut allergy – a paradigm shift? Matthew D. Heath, UK

P075 Mannose decorated exosomes with RNA nanoparticles harboring miR-511-3p protects against allergic asthma Peisong Gao, USA

P076 Single Nucleotide Polymorphism on chromosome 14 associated with Emphysema in local Pakistani population Samra Kousar, Pakistan

P077 Effect of the Rho-kinase inhibitor hydroxyfasudil on airway reactivity, allergic inflammation and remodelling factors in the settings of experimental allergic inflammation of the airwaysSona Franova, Slovakia

P078 Manufacturing and Standardization of Peanut (Arachis hypogaea) Allergen Powder-dnfp for Use as an Oral Immunotherapy: Peanut Flour Source Material Lot Testing Stephen A. Tilles, USA

P079 Selenomethionine attenuates human primary mast cells responses in soy allergy Xiaoli Zhao, Netherlands

P080 Interleukin-33 gene expression and rs1342326 polymorphism in Behçet's disease Zohreh Babalou, UK

Basic Science Oral + Poster AbstractsO25 Mechanisms of Immune Response and Relationship to Clinical Reactivity During Oral Immunotherapy With Peanut (Arachis hypogaea) Allergen Powder-dnfp: Findings From the Phase 3 PALISADE Trial Robert Ryan, UK

O26 Using machine learning approaches for analysis of data collected in a birch pollen AIT trialLorenz Aglas, Austria


O27 Tryptase release does not discriminate between IgE- and MRGPRX2-mediated mast cell degranulationJessy Elst, Belgium

O28 Shrimp Skin Prick Test extracts show critical variability in full allergen repertoire Thimo Ruethers, Singapore

O29 A novel virus-like particle for the treatment of cat allergy Matthew D Heath, UK

O30 NTLA-2002: CRISPR-Mediated Gene Knockout of KLKB1 as a Potential Single-Dose Treatment for Hereditary Angioedema (HAE)Hilary Longhurst, New Zealand

Paediatric Clinical

P081 COVID-19 Vaccine Testing and Administration in Drug-allergic Patients in Hong Kong Agnes Sze-yin Leung, Hong Kong

P082 Insights into Anaphylaxis Episodes during Peanut Oral Immunotherapy Aikaterini Anagnostou, USA

P083 Asking adolescents about adherence to allergy and asthma medicationAlbuzair Almalik, UK

P084 Bronchoalveolar lavage in children with chronic bronchitis and asthma Alla Nakonechna, UK

P085 To feed or not to feed; supervised feeds in a paediatric allergy service Amy Hanley, UK

P086 Multiple food protein induced enterocolitis syndrome (FPIES): case studies of management and impact Anna Conrad, UK

P087 Mixed Method Service Evaluation of Oral Food Challenges in a District General Hospital in the South-West of England Atanu Mukherjee, UK

P088 Associated factors for a positive cow's milk oral food challenge in brazilian population Barbara Cristina Ramos, Brazil

P089 IgE mediated legume allergy in east Mediterranean children: a reflection of multiple food allergies Bulent Sekerel, Turkey

P090 Brands of adrenaline auto injector in Ireland: What brands do caregivers use and are they adequately trained in their administration Caoimhe Cronin, Ireland

45wao-bsaci.org

P091 Faecal IgE in infants with non-IgE-mediated Cow’s Milk Protein Allergy; a first glimpse into its pathophysiology? Caroline Kerbiriou, UK

P092 A pilot randomised controlled trial of mindfulness-based cognitive therapy for parents and carers of children with food allergy Christina Jones, UK

P094 Egg ladder in residual egg allergy post haematopoietic stem cell transplant in DOCK8 deficiencyCiara Walsh, Ireland

P095 Conjunctival allergen provocation tests in children – a real life study Daniela Brandão Abreu, Portugal

P096 Prevalence of self-reported allergic diseases among Korean adolescents during the COVID-19 pandemic: comparison with pre-COVID-19 11-year trends Dong In Suh, Korea, Republic of

P097 Eosinophilic Oesophagitis: Observations of a London Paediatric Gastro-Intestinal and Allergy department Eleanor Buck, UK

P098 Audit of a triaging system for referrals to a secondary care paediatric allergy service Emily Derrick, UK

P099 Family education during admission for an acute wheeze or asthma remains important. Esme Welch, UK

P100 A pilot to evaluate a shortened drug provocation challenge for antibiotic allergies in paediatric outpatients using risk-stratification Eva Wooding, UK

P101 Cyclosporine A 0.1% Cationic Emulsion in Vernal Keratoconjunctivitis: a clinical experience Gaia Bruschi, Italy

P102 Do parents follow a home egg reintroduction advice ladder; 2 year follow up of children with IgE egg allergy who were give home reintroduction advice Heidi Ball, UK

P103 Trends in use of specialised formula for managing cow’s milk allergy in young children Hilary Allen, UK

P104 Exposure to endotoxin modifies the risk of asthma in children with risk variants in 17q21 locus Jack Pepys, UK


P105 Parental attitudes towards food allergy Janefrances Namuli, Kenya

P106 Successful delivery of mRNA COVID-19 vaccine to high-risk children aged 12+ with a history of immediate reaction to Polyethylene glycol (PEG) Jeanne Cloonan, Ireland

P107 An audit of the adrenaline autoinjector prescribing practice of the Evelina children's allergy serviceKatherine Knight, UK

P108 Identifying knowledge of penicillin allergy and barriers to penicillin allergy de-labelling in children: a multi-centre survey in the West Midlands Kene Maduemem, UK

P109 Optimal therapeutic period to achieve sustained unresponsiveness in peanut oral immunotherapy Kosei Yamashita, Japan

P110 The impact of a formal drug challenge on documented allergy status and antibiotic use in children in primary and secondary care Ky-Lyn Tan, UK

P111 The efficacy of dietary management of eosinophilic oesophagitis in oesophageal atresia; a single centre reviewLeanne Goh, UK

P112 Dynamics of reduction of spontaneous activation of basophils after successful subcutaneous immunotherapy with weed allergens Lyudmila Yur'evna, Russian Federation

P113 Allergy to Polyethylene glycol (PEG) ingredient in Pfizer COVID 19 Vaccine: Diagnostic challenge Mahesh Katre, UK

P114 Supplemental zinc therapy in children with asthma: a systematic review Maria Florlean Quinio, Philippines

P115 A combination of epitope and protein specific IgG and IgE antibodies are predictive of baked egg reactive phenotype Maria Suprun, USA

P116 Allergy referrals to Paediatric outpatient clinic during COVID19 pandemic restrictions Marian Abdelsayed, UK

P117 Dupilumab Treatment in Children Aged 6-11 Years with Severe Atopic Dermatitis is Associated with Reductions in Serum Immunoglobulin E and Thymus and Activation-regulated Chemokine Levels Michael J. Cork, UK

47wao-bsaci.org

P118 Antibiotic drug de-labelling in children; a safe and effective secondary care protocol Minal Gandhi, UK

P119 Effect of inhaled corticosteroids on urinary calcium excretion in children with persistent asthma Mohammad Nabavi, Islamic Republic of Iran

P120 Very low total IgE as a potential marker for immunodeficiency in a pediatric population with high incidence of immunodeficiency disorders Mohammed Mohammed Yousuf Karim, Qatar

P121 Choice of allergen-specific IgE testing should be guided by knowledge of local allergen sensitization profiles Mohammed Mohammed Yousuf Karim, Qatar

P122 Evaluation of the paediatric home based food reintroduction service at Bristol Royal Hospital for ChildrenMyriam Kanchanatheera, UK

P124 Dupilumab Provides Long-Term Improvement in Sleep Loss in Children, Adolescents, and Adults with Atopic Dermatitis Peter D. Arkwright, UK

P125 Symptom Freedom and Symptom Severity Reduction in Peanut-Allergic Individuals From Clinical Trials of Peanut (Arachis hypogaea) Allergen Powder-dnfp Oral Immunotherapy: A Post Hoc Analysis Robert Ryan, UK

P126 Can microarray technology replace the traditional ImmunoCAP IgE test? Rona Alkaadi, UK

P127 BATty about peanut allergy Rosalind Capelin-Jones, UK

P128 Reliability of skin prick and specific IgE tests to confirm true allergy in comparison to food challenge in paediatric patients at St George's University Hospital Rosy Wells, UK

P129 Do families reintroduce food at home following successful oral food challenges in hospital? Shazia Majeed, UK

P130 The impact of lockdown on vernal keratoconjunctivitis: an italian experience Simone Centonze, Italy

P131 The voice of the child Sonya Hiremath, UK


P132 Valid diagnostic criteria for the formation of bronchial asthma in children with obstructive bronchitis Tahira Panahova, Bahamas

P133 Parent-reported eczema predicts IgE-mediated food allergy in a tertiary clinic, and is unrelated to regular peanut consumption six months after being recommended to consume Tom Marrs, UK

Paediatric Clinical Oral + Poster AbstractsO13 Early initiation of short term moisturization from birth significantly decreases the rate of AD at 12 months in a high-risk cohort. Dhanis Lad, Ireland

O14 Efficacy of Dupilumab in Quadrants of Elevated- vs Low- Type 2 Biomarkers in Children with Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Ross Thomas, UK

O15 Trajectories of restrictive pattern of lung function FEV1/FVC to physiological peak and their relationship with early life risk-factors and cardiac markers Matea Deliu, UK

O16 Continued Safety of Peanut (Arachis hypogaea) Allergen Powder-dnfp in Children and Teenagers with Peanut Allergy: Pooled Analysis From Controlled and Open-Label Phase 3 Trials Stephen A. Tilles, USA

O17 Evolution of eczema, wheeze and rhinitis from infancy to early adulthood: analysis of four birth cohort studies Sadia Haider, UK

O18 An international Delphi consensus study on the detection and management of milk allergy Hilary Allen, UK

49wao-bsaci.org

Primary Care

P134 Development and content validation of a comprehensive health literacy survey instrument for use in patient populations with asthma during the COVID-19 pandemic Christian Apfelbacher, Germany

P135 Self-reported adverse reactions to foods in adults have increased between 2013 and 2021 in a poor urban population Hannah Wardman, UK

Primary Care Oral + Poster AbstractsO05 Impact of community dietetic leadership in paediatric food allergy on the burden of care for both primary care and families: A service evaluation comparison Lisa Waddell, UK

O06 Prevalence and pattern of milk allergy overdiagnosis in the BEEP trial population Emilia Jackson, UK


Invited speakers

51wao-bsaci.org

Invited Speakers

Roshini AbrahamProf. Clinical Pathology, Director, Diagnostic Immunology Laboratory, Associate Chief, Academic Affairs, Nationwide Children's Hospital and The Ohio State University College of Medicine, USADr. Roshini S. Abraham received her PhD in Immunology in 1996, and completed post-doctoral fellowships in Immunology (1996-2000), and

Clinical Immunology and Biochemistry (2000-2002) at the Mayo Clinic, Rochester, MN. She was on faculty at the Mayo Clinic from 2002-2018. Since September 2018, she has been on the faculty at Nationwide Children's Hospital (NCH) in Columbus, Ohio, and is a Professor of Clinical Pathology at Ohio State University Wexner College of Medicine. She is the Associate Chief of Academic Affairs and the Founding Director of the Diagnostic Immunology Laboratory and Program in the Department of Pathology and Laboratory Medicine at NCH. She is a diplomate of the American Board of Medical Laboratory Immunology (ABMLI), and a fellow of the American Academy of Allergy, Asthma and Immunology (AAAAI) and the Clinical Immunology Society (CIS). She is a Past President of the Clinical Immunology Society (CIS; 2017-2019). She is the Co-Chair of the Immunology Clinical Domain Working Group for ClinGen, and Co-Chair of the Antibody Defects Gene Curation Expert Panel. She has published 122 peer-reviewed articles, 21 book chapters and over 150 abstracts.

Jenny AddisonAllergy specialist nurse, Manchester Foundation Trust, UKJenny Addison graduated from Manchester University after completing the Bnurs program. She began her nursing career as a healthcare support worker at the Northwest lung centre at Wythenshawe hospital which

is where she found her love of nursing. After qualifying, she continued to work within the respiratory field and also gained experience in Oncology working at the Christie hospital’s chemotherapy unit. Jenny has been employed as senior specialist allergy nurse at the allergy centre University Hospital of Manchester NHS Foundation Trust since 2015. In 2019 she gained a post graduate qualification in clinical allergy from Newcastle University. The service is now one of the largest allergy clinics in the northwest with four consultant allergists and a steadily growing nursing team.


Professor Mübeccel AkdisHead of Immuneregulation, Swiss Institute of Allergy and Asthma Research, SwitzerlandDr Akdis has worked at the Swiss Institute of Allergy and Asthma Research (SIAF) since 1995 and received her PhD in Immunology. She worked as a postdoctoral scientist and became a group leader at SIAF, where she

has established her own research group in 2003. Dr Akdis made her habilitation in Zurich University Medical Faculty on Experimental Immunology in 2005 and became a professor in 2015. She has published 267 Peer-reviewed articles, Sum of times cited : 31̀ 800 and her h-index: 83 (98-scopus). She has received research grants and collaborative grants from the Swiss National Foundation, European Union (MeDALL and Predicta) and Sean Parker Seed Grant. She received numerous awards, including International Distinguished Fellow Award of the American College of Allergy, Asthma & Immunology (ACAAI), 2018. EAACI, Paul Ehrlich Award 2020 for Experimental Research. Anerkennungspreis der Regierung des Kantons Graubünden, Kantons Graubunden recognition preis 2020. 2021 Bulent Eczacibasi Medical Science Award.

Cezmi AkdisDirector, Swiss Institute of Allergy and Asthma Research, Switzerland

Cezmi Akdis is the director of the Swiss Institute of Allergy and Asthma Research (SIAF) located in Davos and Ordinarius Professor in Zurich University Medical Faculty. He has honorary professorships from Beijign, Wuhan (China) and Bursa Uludag Universities (Turkey). He is a Senate

Member of the Swiss Academy of Medical Sciences. Cezmi Akdis has published more than 600 peer-reviewed articles. His h-index is 110 and he was selected as a highly cited author consecutively in 2016-2017-2018-2019-2020 and 2021 by Clarivate (Thomson Reuters). Cezmi Akdis acted as the President of the European Academy of Allergy & Clinical Immunology (14’000 members) between 2011-2013. He was the editor of Global Atlases of Allergy, Asthma I-II, Chronic Rhinosinusitis and Allergic Rhinitis. He was the founder and organizer of the World Immune Regulation Meetings, Davos I-XV (600-1000 participants). He is currently the Editor-in-Chief of Allergy, impact factor 13.15. Cezmi Akdis’s major scientific contributions are on immune regulation and allergen tolerance, plasticity of antigen-specific T cells 1995, human T regulatory cells 1996, immune suppressive role of histamine receptor 2 2000, human Type 2 NK cell subset 2001, human regulatory NK cells 2007, regulatory innate B cell subset 2017, regulatory innate lymphoid cells 2019. His current research is the continuation of his epithelial barrier hypothesis studies starting from mechanisms of eczema 2000, mechanisms of epithelial shedding in asthma and chronic rhinosinusitis 2003, endotypes of asthma, chronic rhinosinusitis and atopic dermatitis 2011, epithelial barrier hypothesis for the development of allergic and autoimmune diseases 2015 - 2022. Cezmi Akdis is an author of more than 40 publications on COVID-19 and SARS-CoV-2 including pathophysiology, risk factors, severity, patient characteristics and how to handle allergy and asthma patients during the pandemic.

53wao-bsaci.org

Ignacio J Ansotegui, Head of Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Spain

Ignacio J. Ansotegui is the Head of the Department of Allergy and Immunology at Hospital Quironsalud Bizkaia in Bilbao, Spain and also currently serves as Immediate Past President of the World Allergy

Organization (WAO), President of Southern European Allergy Societies (SEAS), Treasurer of Global Asthma Association (INTERASMA), Member of the Board of Directors of the Latin-American Society of Allergy, Asthma and Immunology (SLAAI) and President of Food Safety and Allergy Prevention Foundation (FSA). Prior to this he was working as Consultant Allergist and Clinical Immunologist at Royal Hospitals as well as Honorary Senior Lecturer at Queen’s University of Belfast, United Kingdom. Previous experience was carried out in diverse health systems of Sweden, Italy and Spain. After finishing his medical studies at the University of Basque Country in Bilbao, Ignacio J. Ansotegui moved to the Department of Immunology at the Karolinska Institute and Department of Clinical Immunology at the Karolinska Hospital of Stockholm, where he completed his Spanish PhD studies and specialization in Immunology, respectively. 5 years later, at the University of Rome “La Sapienza”, he got his second specialty in Allergology and Clinical Immunology. He is also a specialist in Occupational Medicine. For more than 20 years, Dr. Ansotegui has been serving as officer in several international scientific societies of Allergy, Asthma and Clinical Immunology (EAACI 1999-2010, INTERASMA 2003-present, SEAS 2007-present, SLAAI 2008-present and WAO 2010-present). Between 2008 and 2017 he has also been secretary of the European CME Accreditation Committee. And in 2008, he was the President of the European Congress of Allergy and Clinical Immunology that was held in Barcelona. Prof Ansotegui has published over 150 peer reviewed articles and has been editorial board member of several journals of Allergy and Immunology.

Rebecca BattPaediatric Allergy Advanced Nurse Practitioner, Evelina London Children’s Hospital, UK

Rebecca qualified as an RGN/RSCN in 1993 from Sheffield School of Nursing. She spent ten years working in PICU at Great Ormond Street and Toronto Sick Children’s Hospital. She gained a BSc (Hons) from LSBU in

Paediatric Intensive Care Nursing in 2004. She was a Practice Educator at GOSH before starting as a Nurse Specialist at Asthma UK. She began her career in allergy in 2007 when she became a Paediatric Allergy CNS at King’s College Hospital. She gained the MSc in Allergy from Imperial College, London in 2011 with Distinction. She is now an Advanced Nurse Practitioner at The Evelina London Children’s Hospital and is a Non-Medical Prescriber. Rebecca is the Senior Clinical Lead for the nursing team and regularly speaks at national study events and conferences. She lectures at LSBU on the Advanced Nurse Practitioner Pathway and the Non-Medical Prescribing Course and on the Allergy MSc at Imperial College. She is a Course Director for the Allergy Academy and organises national study events for allergy healthcare professionals across the country. Rebecca is also a member of the BSACI Nurses Committee as well as on the planning committee for this years’ conference.


Professor Jonathan A. BernsteinProfessor of Clinical Medicine, University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology and Partner of Bernstein Allergy Group and Bernstein Clinical Research Center, USA

Jonathan Bernstein is Professor of Clinical Medicine in the Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology at the University of Cincinnati Medical Center, a partner of the Bernstein Allergy Group and Clinical Research Center and Editor-In-Chief of the Journal of Asthma. He received his MD from the University of Cincinnati College of Medicine (1981-1985), completed his residency in Internal Medicine at the Cleveland Clinic Hospital (1985–1988) and Allergy/Clinical Immunology training at Northwestern University (1988–1990). His research interests are related to environmental impact on asthma, chronic urticaria, angioedema, atopic dermatitis, chronic rhinitis subtypes, chronic cough, and women’s health issues. He is Secretary Treasurer of the AAAAI and a member of the WAO board of directors, the AAAAI foundation, GINA advocacy council and HAEA organization medical advisory board. Dr. Bernstein is the recipient of the AAAAI Distinguished Clinician Award (2019) and the WAO Outstanding Clinician Award (2019). He has authored over 400 peer-reviewed articles and book chapters and is the editor of five books pertaining to asthma, rhinitis and immunodeficiency.

Dr Patrizia BonadonnaAllergist, Allergy Unit, Verona University Hospital, Verona, Italy

Patrizia Bonadonna, M.D., Ph.D. is a clinician-scientist who works form over 20 years in Allergy and Immunology Department of University of Verona. She is Chief of Allergy in the Multidisciplinary Outpatient Clinic

Group of Mastocytosis of Verona that is recognized centers of excellence from European Network of Mastocytosis which provides diagnosis, management, and treatment options for patients with mastocytosis and mast cell activation disorders, Chief of Outpatient Clinic Department of Drug Allergy and Hymenoptera Venom Allergy of Allergy Unit of Verona. She was from 2012 to 2016 Secretary of Interest Group on Drug Allergy for the European Academy of Allergy And Clinical Immunology She is Member of European Network of Mastocytosis and Medical Advisory Board for The Mastocytosis Society (TMS) in USA.The main topic of research of her are:• Clonal and non Clonal Mast Cell disorders• Drug allergy• Hymenoptera venom allergy ( diagnosis and immunotherapy)She has published more than 130 article about these topics.

55wao-bsaci.org

Professor Luis CaraballoDirector, Institute for Immunological Research, University of Cartagena, ColombiaProfessor Caraballo is a Doctor in Medicine and Surgery, Master in Immunology, PhD in Pharmaceutical Sciences and Specialist in Clinical Allergology. Honorary Professor, Senior Professor of Medicine and Allergy and Director of the Institute for Immunological Research,

University of Cartagena, Cartagena de Indias, Colombia. He is Director of the Biomedical Sciences PhD Program of the University of Cartagena. For 40 years he has been committed to educating undergraduate and graduate (Master and PhD) students. Author of more than 150 scientific articles and several books and book chapters. He has made and is currently making significant contributions to the field of experimental allergy, basically studying the genetic and environmental factors for asthma in the tropics. He is an expert on mite allergens and has discovered several allergens from Blomia tropicalis as well as allergens from the nematode Ascaris lumbricoides and their importance in the pathogenesis of allergic diseases in the tropics. Current Associated Editor of WAO Journal and Frontiers in Allergy. Former member of the WAO Board of Directors and Past President of the Colombian Association of Allergy Asthma and Immunology.

Dr Victòria Cardona Head of Allergy Section, University Hospital Vall d'Hebron, Spain

Victòria Cardona, trained in medicine (1982-8) and specialised Allergy (1994-7) at the Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Spain. She achieved her Doctoral Degree in 2002. She is

currently Head of the Allergy Section, Department of Internal Medicine, at the Hospital Universitari Vall d’Hebron. Her main research and publication interests are, among others, anaphylaxis, mediators, co-factors, immunotherapy and patient reported outcomes. She has published more than 70 articles. She has been EAACI-Vicepresident of Communications and Membership (2009-2013), and has coordinated the anaphylaxis committee of the World Allergy Organization and the Latin-American Society of Allergy. She is member of the Editorial Board of the journal Clinical and Translational Allergy and Journal of Investigational Allergology and Clinical Immunology.

Thomas B. CasaleProfessor, University of South Florida, USA

Dr. Casale is Professor of Medicine and Pediatrics and Chief of Clinical and Translational Research at University of South Florida in Tampa. He is also Chief Medical Advisor, Food Allergy Research and Education (FARE). He is a member of the American Society for Clinical Investigation, and a

past member of the Board of Directors of the American Thoracic Society, World Allergy Organization (WAO), American Board of Allergy and Immunology (Chair 2005) and the American Academy of Allergy, Asthma and Immunology (AAAAI). He is a Past President of the AAAAI and was the Executive Vice President for 10 years. He has published over 475 scientific papers, reviews, and chapters primarily on asthma, COPD and allergic diseases; organized and directed more than fifty CME programs for local and national meetings; and been a member of the planning committee for five World Asthma Meetings. He has been on the editorial boards of multiple journals including JACI, Annals of Allergy, JACI Practice and European Respiratory Journal.


Mariana CastellsDirector of Mastocytosis; Director of Drug Hypersensitivity & Drug Desensitization, Brigham and Women’s Hospital and Harvard Medical School, USA

Mariana Castells, M.D., Ph.D. is a clinician-scientist with over 30 years of experience in allergy and immunology. Additionally, she is a Professor of

Medicine at Harvard Medical School with over 200 publication. She is the Director of the Brigham and Women’s Mastocytosis Center one of the few nationally and internationally recognized centers of excellence which provides diagnosis, management, and treatment options for patients with mastocytosis and mast cell activation disorders, which are rare and potentially deadly disorders currently addressed with Tyrosine Kinase Inhibitors. Additionally, she is the Director of the Drug Hypersensitivity and Desensitization Center at Brigham and Women’s and Dana Farber Cancer Institute which provides over 900 high risk desensitization’s per year for over 20 years to patients with cancer, severe infections and inflammatory diseases who are allergic to their first line therapy, increasing their life expectancy and quality of life.

Yoon-Seok ChangProfessor,Seoul National University Bundang Hospital, Republic of Korea (South Korea)

Professor Yoon-Seok Chang is the Head of the Division of Allergy and Clinical Immunology, the Department of Internal Medicine, Seoul National

University Bundang Hospital, Seoul National University since 2003. He received his Doctor of Medicine, Master of Science, and Ph.D. in Medicine from Seoul National University. He has published more than 270 peer-reviewed papers (229 original, 47 review articles: h-index 48), 21 editorials, 16 books (chapter author), and 3 patents. His main research topics are asthma, allergic rhinitis, chronic cough, drug allergy, anaphylaxis, and community medicine. He is also the Head of the Medical Research Collaboration Center of the hospital, and the Head of Gyeonggi-Do Atopy·Asthma Education Information Center. He is an active member of academic societies: Secretary General (Korean Academy of Asthma, Allergy, and Clinical Immunology (KAAACI), Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI)), and the Editor-in-Chief (Asia Pacific Allergy), and the Editorial board member (Allergy, AAIR, Clinical Translational Allergy, Immune Network). In WAO, he has been served at the Healthcare Delivery Committee (2014-2015), Drug Hypersensitivity Reactions Committee (2018~current), Adult Asthma Committee (2020~current), the Steering Committee for World Allergy Week 2022 (Chair), the House of Delegate (2018-2019), and as a WAO Board member (2020~current).

57wao-bsaci.org

Dr Andrew ClarkConsultant in paediatric allergy, Cambridge University Hospitals NHS Trust, UK

Dr Andrew Clark is a consultant and associate lecturer in paediatric allergy at Cambridge University Hospitals Trust, UK. His research interests have spanned the period of the food allergy epidemic, addressing

early key clinical questions and informing international allergy practice. Early focus areas include the natural history of food allergy, diagnostic tests, the effect of clinical interventions and novel diagnostic techniques. Recently, he led a multicentre randomised trial which estimated the effects of exercise and sleep restriction on reaction thresholds and severity in severe food allergy (TRACE study). Over a decade ago he initiated a development programme for peanut oral immunotherapy, publishing the first ever randomised controlled trial using this technique. The successful outcome led to the founding of Camallergy, and the developmeant of a candidate drug, ready for global Phase III trials. An early access treatment programme in Cambridge has enrolled over 220 peanut-allergic children since 2015. He is past-chair of the BSACI Standards of Care Committee and during his tenure produced six National Guidelines, many of which were informed by his early research and which are highly regarded and referenced throughout the world. In 2020, Dr Clark received the William Frankland Award in recognition of his outstanding contribution to clinical allergy.

Lucy CommonAdvanced Clinical Nurse Specialist,Northern Care Alliance, UK

Lucy Common is an Advanced Clinical Nurse Specialist in Immunology for the Northern Care Alliance, Salford where she has been in post since 2010. Prior to this she was an adult nurse specialist in allergy for 3 years

at Guys and St Thomas' Hospital, London. She studied at Kings College London (BSc (Hons) Nursing Studies) followed by further studies at London School of Hygiene and Tropical Medicine (Diploma in Tropical Nursing) Southampton University (MSc Allergy) and Salford University (Non Medical Prescribing). Lucy leads a small, dedicated and dynamic nurse specialist team at Salford where quality and patient experience is at the centre of their work. She has experience in running nurse-led general allergy clinics and Immunotherapy clinics and also being involved in drug desensitisation and drug and food challenge procedures


Maria CrainAPRN, CPNP, Advanced Practice Nurse/Pediatric Nurse Practitioner, University of Texas Southwestern Medical Center, USA

Maria Crain, APRN, CPNP, is a pediatric nurse practitioner that specializes in food allergies. She received her Master’s degree in nursing at New York University. She worked as a nurse practitioner at the Jaffe Food

Allergy Institute of Mount Sinai Medical Center for five years. Afterwards, she moved to Dallas, Texas and has been the food allergy nurse practitioner at Children’s Health/UT Southwestern Medical Center for the past 12 years. She performs food challenges, and sees new and established patients. She also serves as co and sub investigator on multiple food allergy studies. She is involved in the AAAAI and recently served as the co-chairman of the Allied Health Education Committee. She attends and speaks at multiple allergy conferences and meetings in the United States. She is honored to be able to attend and speak at this year’s WAO BSACI conference.

Professor Adnan CustovicProfessor of Paediatric Allergy, Imperial College London, UK

Adnan Custovic is Professor of Paediatric Allergy at Imperial College London. His professional training consisted of a Specialist training in Paediatrics (1987-91), and successive appointments as Clinical Research

Fellow and Specialist Registrar in Allergy (University Hospital of South Manchester, 1992-98). This period saw him awarded M.Sc. (1991), M.D. with Gold Medal (1996) and Ph.D. (2000). He was promoted to a professorship at the University of Manchester in 2002 and moved to Imperial College in 2015. In 2020, he was elected to the Fellowship of the UK Academy of Medical Sciences. In 2019, he was granted membership of the Academy of Sciences and Arts of Bosnia and Herzegovina (ANUBiH). In 2015 he was awarded a prestigious ERS Gold Medal for research in asthma. In 2013 he received the BSACI William Frankland Medal for outstanding contributions to clinical allergy in the UK. He delivered numerous prestigious keynote/named lectures. He publisher >350 papers in peer-reviewed journals, with a current h-index of 100. He serves at the Board of Directors of the World Allergy Organisation and has served as a Secretary of the BSACI for two terms, and as President of Asthma section of the EAACI. He has supervised 18 PhD/MD students to completion.

59wao-bsaci.org

Professor Stephen DurhamProfessor of Allergy and Respiratory Medicine, Imperial College London and Royal Brompton Hospital London, UK

Stephen Durham is Professor of Allergy and Respiratory Medicine and Head of Allergy and Clinical Immunology at National Heart and Lung Institute, Imperial College London and Honorary Consultant at Royal

Brompton Hospital. He trained at Downing College Cambridge and Guy’s Hospital London. He completed his higher specialist training in respiratory medicine in Oxford before returning to the Brompton in 1988. Over 40 years Dr Durham’s research has been into basic mechanisms of allergic rhinitis and asthma, local IgE regulation and translational clinical and mechanistic studies of allergen immunotherapy. He has led a general allergy and asthma clinic and a specialist combined medical/surgical rhinology service. He is Past President of the British Society for Allergy and Clinical Immunology. He is a Steering Committee Member of the Immune Tolerance Network, NAIAD and chaired the Allergy Advisory Group of the Immune Tolerance Network (2012-20). He has an h-index of 150 and has over 400 original peer-reviewed publications.

Professor Motohiro EbisawaDirector of Clinical Research Centre for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Japan

Motohiro Ebisawa is the Director of Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital and the Professor of the Jikei University School of Medicine. He graduated from the Jikei

University School of Medicine in Tokyo in 1985 and took short visiting resident course in the department of Pediatrics at St. Thomas Hospital in London, UK. He completed his postgraduate course at the Jikei University School of Medicine, where he earned his PhD. He did postdoctoral fellowship on the analysis of “eosinophil selective recruitment” in Dr. Robert P. Schleimer’s laboratory at Johns Hopkins University from 1991-1993. He also had a chance to visit Dr. Hugh Sampson’s food allergy unit regularly during his fellowship. After coming back to Japan, he started food allergy practice and research at Sagamihara National Hospital since 1995. He has published more than 200 papers on international journals in addition to numerous numbers on domestic ones. He is a leading expert in food allergies in Japan and currently serves as the President of World Allergy Organization, Japanese Society of Allergology and Asian Pacific Academy of Pediatric Allergy, Respirology and Immunology. He also serves as associate editor of Pediatric Allergy and Immunology.


Nadim and Tanya Ednan-LaperouseNatasha Allergy Research Foundation, UK

The story of the death of 15-year-old Natasha Ednan-Laperouse touched the country’s heart. On 17th July 2016 Natasha died from a severe allergic reaction caused by her unwittingly eating a baguette containing sesame seeds, to which she was allergic. Her high-profile inquest in 2018 was

reported and followed around the world. The coroner’s hard-hitting conclusion that her death was preventable, incensed our nation. Nadim and Tanya Ednan-Laperouse Natasha’s parents, founded The Natasha Allergy Research Foundation, determined that no other family should have to suffer the same devastating and unnecessary loss that they did. Together with their son, Alex, they campaigned for Natasha’s Law, and with overwhelming support from the public during consultation, this major change to UK food labelling laws came into force from October 2021. It means that all food ‘pre-packed for direct sale’ must have a label that details all ingredients and allergens. Today, Nadim and Tanya are Trustees of the Natasha Allergy Research Foundation and are giving a voice to the two million people in the UK living with food allergy. With a vision of ‘making allergy history’, Natasha’s Foundation is the only UK charity dedicated to funding allergy medical research to treat, prevent and eradicate allergic disease, starting with food allergy. The Foundation also works to increase awareness and education about the dangers of food allergy and campaigns for policy change to create a world that is safe for all individuals living with allergies. This includes the current campaign calling on the Government for an Allergy Tsar.

Dr Alessandro FiocchiDirector of Allergy, Pediatric Hospital Bambino Gesù IRCCS, Vatican City, Italy

Alessandro Fiocchi MD is the Director of Allergy at the Pediatric Hospital Bambino Gesù, Rome, Vatican City. Since 2001, he has organized international meetings in Italy, USA, Thailand, Argentina, and other

countries. Author of the WAO DRACMA guidelines on cow’s milk allergy in 2010, he inspired the GLAD-P guidelines on allergy prevention by probiotics (2015), prebiotics (2016), Vitamin D (2017). Since 2014 he serves as Editor-in-Chief of the World Allergy Organization Journal. He leads the Food Allergy Committee at WAO for 2020 – 2022. He organised the first virtual WISC in July 2020.

Dr Louise FlemingClinical reader, Paediatric Respiratory Medicine, Imperial College London, UK

Dr Louise Fleming is a Reader in Respiratory Paediatrics at the National Heart and Lung Institute and Consultant Respiratory Paediatrician at the Royal Brompton hospital. She is a member of the GINA (Global

Initiative for Asthma) Science Committee, founding member of the ERS supported Clinical Research Collaboration SPACE (Severe Paediatric Asthma Collaboration in Europe), member of the NHS England Children and Young People’s asthma oversight group (chair of the severe asthma workstream) and Asthma UK Senior Clinical Fellow. Her research interests include monitoring asthma, with a focus on adherence, phenotyping severe asthma and preschool wheeze and use of biomarkers. Clinically she looks after children with a wide range of respiratory problems.

61wao-bsaci.org

Professor Adam FoxConsultant Paediatric Allergist, Evelina London Children’s Hospital, UK

Adam read Medicine and Neuroscience at Cambridge University. He spent 9 years as clinical lead for Allergy at Guy’s & St Thomas’ Hospitals, London. After 3 years as Clinical Director for Specialist Ambulatory

Medicine, he took up the post of Deputy Medical Director in 2018. He is also Professor of Paediatric Allergy at King’s College London & founding Director of the KCL Allergy Academy, which was a finalist at the BMJ Awards in 2018. Adam chaired the RCPCH Care Pathway for Food Allergy and was a member of the National Institute of Healthcare and Clinical Excellence (NICE) clinical guideline development group for the assessment and diagnosis of food allergy. He has been an expert committee member on two MHRA specialist groups and a NICE Health Technology Appraisal and was appointed a NICE non-specialist guideline chair in 2021. He was elected BSACI President, the first Paediatrician to hold this position, from October 2018. Adam was awarded ‘Paediatric Allergist of the Year’ from Allergy UK in 2007. His doctoral thesis on peanut allergy received the Raymond Horton-Smith prize from Cambridge University in 2012 and he was included in The Times ‘Britain’s 100 Best Children’s Doctor’s’. Adam received the William Frankland Award from the BSACI in 2015.

James GardnerAllergy Nurse Consultant, Great North Children’s Hospital, Newcastle, UK

James qualified at Great Ormond Street Hospital in London as a Paediatric Nurse and, after working in general paediatrics/haematology, joined the allergy team at St Mary’s Hospital, London then for many years was the lead allergy nurse at the Royal Free Hospital & Royal National

Throat, Nose and Ear Hospital, both in London. He is currently the Children’s and Young Persons Allergy Nurse Consultant at the Great North Children’s Hospital in Newcastle and also Associate Clinical Lecturer in Newcastle University where he is Lead of the Allergy E-module programme. He previously completed his MSc in Allergy from the University of Southampton and focused on the use of component resolved diagnostics in peanut allergy. He is the current Secretary of the Allied Health working group in the European Academy of Allergy and Clinical Immunology. He has been involved in several European task force groups through the academy including competencies for allied health working allergy M-health and social media. His main research interests are in food allergy, allergic rhinitis and MHealth. He is involved with many food allergy support groups and regularly on various allergy social media groups (Twitter @allergynurseuk).


Professor Andrew Gennery,Sir James Spence Professor of Child HealthProfessor and Honorary Consultant in Paediatric Immunology + HSCT, Translational and Clinical Research Institute, Newcastle Universityand Great North Children's Hospital, Newcastle upon Tyne, UK

Dr Gennery is Professor in Paediatric Immunology and Haematopoietic Stem Cell Transplantation at Newcastle University and Honorary Consultant for the Northern Supra-Regional Bone Marrow Transplant Unit for SCID and related disorders, at the Great North Children’s Hospital, Newcastle upon Tyne. During a year of post-doctoral studies with Anne Durandy and Alain Fischer at the Necker Hospital, Paris he was involved in the discovery of Cytidine Deaminase, critical for class switch recombination and somatic hypermutation. Research interests include immunoreconstitution following HSCT for IEI, long-term outcomes of HSCT for IEI (and in particular CGD and SCID), DNA repair disorders and their appropriate treatment and DiGeorge Syndrome. He has adapted new methods of T-cell depletion for patients with IEI, established extracorporeal photopheresis for treatment of children with GvHD and is exploring use of defibrotide for treatment of non-VOD endothelial cell activation disorders post-HSCT. He is a member of ESID and EBMT, recently chaired the ESID/EBMT Inborn Errors Working Party, the ESID Clinical Working Party and ERN-RITA Guidelines Working Party. He is Co-chair of CIBMTR Primary Immune Deficiencies, Inborn Errors of Metabolism and other NMMD Working Committee. He has published over 370 papers on IEI, has co-authored important multi-centre publications on the outcomes of cohorts of children with rare IEIs following HSCT, and contributed to relevant chapters in several major textbooks.

Dr Sandra N. González-DíazHead and Professor of the Regional Center of Allergy and Clinical Immunology, Hospital Universitario “Dr. José Eleuterio González” y Facultad de Medicina, Universidad Autónoma de Nuevo León (UANL), Monterrey, Nuevo León, Mexico and Director of International Relations, UANL University Autonoma de Nuevo León, Mexico

Dr. Gonzalez-Diaz is the Head, Professor and Director Program of Allergy and Clinical Immunology ( WAO Center of Excellence and CONACYT )Division at the Medical School and University Hospital from Universidad Autonoma de Nuevo Leon (UANL) in Monterrey NL, México, Past President of the Mexican College of Allergist and Immunologist CMICA, Past President LatinAmerican Society SLAAI , Actual President of Mexican Board of Allergy and WAO Board Member; Chairman of Education & Training Programs in WAO as well Co-Chair Committee Atopic Dermatitis and Medical Devices, Co-Editor-in-Chief of Alergia Journal, Revisor Journal Medial Press (Dovepress) author of many papers, author of Allergy Books, with a specialist interest in Skin Allergy : Atopic Dermatitis, Urticaria, etc, Respiratory Allergy / asthma, Allergic Rhinitis, Rhinosinusitis) , Food Allergy and in Multisystemic Allergy and Chemical Mediators.

63wao-bsaci.org

Dr Clive GrattanConsultant Dermatologist, St John’s Institute of Dermatology, Guy’s Hospital, UK

Dr Grattan is a Consultant Dermatologist with a special interest in allergy including mast cell disease presenting in the skin, including mastocytosis and mast cell activation disorders. He is Co-Editor-in-Chief of Clinical and

Translational Allergy and author of many papers and chapters on urticaria and related subjects. He leads the tertiary referral Urticaria clinic at St John’s Institute of Dermatology, London and works closely with colleagues in Haematology and Allergy at Guy’s Hospital.

Dr Kate GrimshawHighly Specialist Allergy Dietitian, Salford Care Organisation, UK

Kate Grimshaw qualified as a dietitian in 1989 after completing a Post Graduate Diploma in Dietetics (Her first degree was in Human Biology). She has since worked in a number of clinical dietetic posts. In 1995 she

completed her MSc in Human Nutrition and in 2003 gained a post-graduate diploma in Allergy. In 2012 she completed her PhD on infant feeding practices in the first year of life and the development of food allergy. Whilst food allergy prevention remains a keen interest Kate is also interested in the aetiology and treatment of food allergy and also the nutritional adequacy of exclusion diets in children and adults. In September 2018 she moved to work at Salford Royal NHS Foundation Trust as dietetic manager, but she continues to work clinically within the food allergy field and provides dietetic support to patients with both IgE and Non-IgE mediated food allergy at Salford. As well as her research, clinical and management roles, Kate lectures on the Food Allergy Module of the MSc in Allergy at the University of Southampton and also to University Dietetic Training programs. She is also involved in the development of Food Allergy Guidelines with EAACI and Ga2len.


Susanne HalkenPediatric Allergologist and Professor in Paediatric Allergology, Odense University Hospital and University of Southern Denmark

Susanne Halken is employed as consultant Pediatric Allergologist and Professor in Paediatric Allergology, Odense University Hospital and University of Southern Denmark. She received “The 10th Gold Medal

of the Foundation for Allergy Research in Europe (FARE)”, EAACI 1998 for research on allergy prevention, and obtained the degree as Doctor of Medical Sciences (DMSc) with the thesis “Prevention of allergic disease in childhood. Clinical and epidemiological aspects of primary and secondary allergy prevention” at The Medical Faculty of The University of Southern Denmark 2004. She has published 169 scientific papers, Hirsch index (Web of Science) 49 and been speaker at numerous international scientific congresses/meeting. She has been Chairman for Board of Section of Pediatrics and member of ExCom of EAACI 2009-2011; Scientific Programme Committee Coordinator and adjunct member of ExCom of EAACI 2015-2018 and member of several EAACI Task Forces incl. “Food Allergy Anaphylaxis Practical Guidelines”, “Allergen Immunotherapy Guidelines” and chairperson for the TF, which updated EAACI Systematic Review and Guidelines on prevention of Food Allergy, published 2021. She is member of EAACI food allergy guideline group, developing updated guidelines on diagnosis of food allergy and member of GA2LEN food allergy guideline group, developing an updated guideline on food allergy management.

Kathryn HaworthAllergy and Immunology Specialist Nurse, Lancashire and South Cumbria Teaching Hospitals NHS Foundation Trust, UK

Kathryn Joined the Allergy and Immunology Service based at Royal Preston Hospital in 2014 and is part of a team caring for people with

Immunodeficiency, HAE, Allergies and Chronic Spontaneous Urticaria and Angioedema. She was previously Lead Research nurse at the Oxford Vaccine Group for Adult vaccine studies. Kathryn is originally from the Preston area, but she has also lived and worked in Bristol and Oxford.

65wao-bsaci.org

Professor Sir Stephen Holgate MRC Clinical Professor of Immunopharmacology, Faculty of Medicine, University of Southampton, UK

Stephen Holgate is Medical Research Council Clinical Professor of Immunopharmacology and honorary consultant physician at the Faculty of Medicine, University of Southampton, UK. He has utilised many

approaches to study asthma. and published in excess of 1000 peer review papers, has been a co-editor of Middleton’s Allergy: Principles and Practice for the last 4 editions and is cofounder of Synairgen, to develop inhaled interferon beta for viral respiratory diseases, including COVID-19. He is a Past President of the BSACI, BTS and CIA He has been recipient of a number of personal awards including the BSACI William Frankland Award and Jack Pepys Lectureship, the King Faisal International Prize in Medicine, the J Allyn Taylor International Prize in Medicine (Canada) and the BTS Medal. He has chaired a number of Government Committees on Air Pollution and currently is Special Advisor to the RCP on Air Quality and UKRI/Met Office Clean Air Champion. He was appointed by the Queen to Commander of the Order of the British Empire (CBE) for his contributions to Clinical Science in 2011 and received a Knighthood (KBE) in the 2020 Queen’s Birthday Honours for Medical Research.

Dr Valerie HoxAssistant Professor, Cliniques Universitaires Saint-Luc, Belgium

Valerie Hox is an academic rhinologist with a strong background and interest in translational rhinology research and sinonasal surgery. After finishing her PhD in airway immunology at the KULeuven in 2012, she

spent 2 years as a postdoctoral research in the laboratory of Allergic Diseases at the NIH, in Bethesda, MD, USA. She returned to Belgium to finish her clinical ENT training and got accepted for the Rhinology/anterior skull base fellowship at Queen Elizabeth Hospital, Birmingham under supervision of S. Ahmed. After completion, she got an academic position at the Cliniques Universitaires Saint-Luc in Brussels, including an assistant professorship at the UCLouvain in Brussels. She has a specific focus on medical and surgical treatment of inflammatory nose and sinus disease and studies the mucosal immunological pathways as well microbiome-immune interactions in these diseases.

Dr Christina JonesReader in Clinical Health Psychology, University of Surrey, UK

Dr Christina Jones is a Reader in Clinical Health Psychology at the University of Surrey and is a Chartered Member of the British Psychological Society. She is also lead for the Applied Clinical & Health

Psychology Research Group. Chrissie currently supervises Trainee Clinical Psychologists doctoral theses and her main research interests are in developing accessible psychological and behavioural interventions to improve health and wellbeing for those living with and affected by atopic conditions. Chrissie has expertise in multi-method evaluations and has a strong background in qualitative methodology which has helped her assess patient preferences in a range of health care contexts from the design of adrenaline auto-injectors to patient reported outcome measures. She has expertise in synthesising current evidence using systematic reviews and meta-analysis.


Professor Marek Jutel, M.DProfessor and Head, Department and Clinical Immunology, Wroclaw Medical University, Poland & President of EAACI

Marek Jutel graduated from the Wroclaw Medical University, Wroclaw, Poland. He is full professor of allergy, clinical immunology and internal medicine and Head of the Department and Clinical Immunology of

the Wroclaw Medical University. Marek Jutel was trained and conducted research in Poland, Switzerland and Germany. In 2012-2014 he was the chairman of the Scientific Programme Committee and a member of the board (Executive Committee- since 2009) of the European Academy of Allergology and Clinical Immunology (EAACI). He served as EAACI Treasurer 2015-2019 and is currently the President of EAACI since 2019. Prof. Jutel has authored more than 300 scientific publications, including in the journal Nature. He contributed to a number of guidelines and position papers on the management of allergic and immune mediated diseases published by EAACI and other scientific organisations. His main interests include mechanisms of immune tolerance, allergen specific immunotherapy and biologicals. He pioneered in the use of recombinant allergens in the treatment of allergic diseases.

Dr Kenji KabashimaKyoto University Graduate School of Medicine

Dr. Kabashima was born in Japan in 1970. He graduated from Kyoto University in 1996 and was trained in Medicine/Dermatology at the United States Naval Hospital in Yokosuka Japan, Kyoto University Hospital, and University of Washington Medical Center. He started research

on bioactive lipid mediators at Kyoto University, which led to a PhD (under Prof. Shuh Narumiya). Then he studied at the Department of Dermatology, Kyoto University Graduate School of Medicine (Prof. Yoshiki Miyachi), UCSF (Prof. Jason Cyster), and University of Occupational and Environmental Health (Prof. Yoshiki Tokura). Currently, he is a chair/professor at the Department of Dermatology, Kyoto University Graduate School of Medicine, Japan, a principal investigator at the SRIS/SIgN, Singapore, and visiting consultant at the National Skin Centre, Singapore. His main interests include the mechanism of inflammatory skin diseases (atopic dermatitis, contact dermatitis, and psoriasis) in mice and humans, and 3D-visualization of the skin using two-photon microscopy. His hobbies are marathon (2:54:38), trail running (Ultra Trail du Mont Blanc 170 km), golf, climbing, and travelling.

67wao-bsaci.org

Dr Luciana Kase TannoUniversity Hospital of Montpellier,Institute Desbrest of Epidemiology and Public Health, INSERM, University of Montpellier, France

Dr. Luciana Kase Tanno graduated in Medicine in 2001. After training in Internal Medicine (2002-2004), she specialized in Allergy and Clinical

Immunology at the University of São Paulo, where she developed her PhD project (2011-2014). In 2006, she completed the residency years and became a Board Certified Allergist in Brazil as a member of the Brazilian Association of Allergy and Immunology (ASBAI). Dr. Tanno has worked as a hospital practitioner and medical assistant of the Department of Allergy of public and private hospitals in São Paulo (Hospital Sírio-Libanês, Hospital Nipo-Brasileiro, Servidor Público Estadual de São Paulo Hospital), contributing with the training of residents from 2013 to 2015. Professor in health science – Allergy and Clinical Immunology at the Postgraduate Program in Health Sciences, Medical Assistance to the São Paulo State Civil Servants since 2014, developed her post-doctoral fellowship at Departement of Pneumologie and Addictologie, Hôpital Arnaud de Villeneuve – CHU de Montpellier and the Sorbonne Universités, Paris, where she is also affiliated. Since 2012, together with Professor Demoly, she has been moving efforts for the representation of allergic and hypersensitivities through the World Health Organization (WHO) International Classification of Diseases (ICD) 11th revision.

Dr Hiroshi KawasakiSenior Research Scientist, RIKEN Center for Integrative Medical Sciences, Japan

Hiroshi Kawasaki received the M.D. and Ph.D. degrees from Keio University School of Medicine in 2004 and 2012, respectively. From April 2006, he entered the Department of Dermatology, Keio University School

of Medicine. From July 2011 to March 2013, he was research resident with the Association for Preventive Medicine of Japan. From 2013 to 2015, he worked as a dermatologist at Tokyo Electric Power Company Hospital and Kitasato University Kitasato Institute Hospital. From July 2016 to March 2020, he was a Senior Research Scientist with Riken Medical Sciences Innovation Hub Program at RIKEN. From April 2019, he is also an adjunct lecturer in the Department of Dermatology, Keio University School of Medicine. He is currently a Senior Research Scientist with RIKEN Center for Integrative Medical Sciences.His research interests include data-driven studies of atopic dermatitis, skin microbiome, and skin barrier research.


Dr Rebecca KnibbAssociate Professor in Psychology, Aston University, UK

Dr Rebecca Knibb is an Associate Professor in Health Psychology and a practitioner Health Psychologist with 25 years of experience of conducting research into the psychological impact of allergies and has

published over 100 peer-reviewed papers and conference proceedings in this field. Her research interests include the health-related quality of life and mental well-being of children, adolescents and parents who are managing long term conditions, particularly allergic conditions and asthma. She is involved in the development of strategies to help families cope through CBT based behaviour change methods and is particularly interested in how children cope with the transition to adolescence and cope with leaving home. She sits on a number of European Association for Allergy and Clinical Immunology Task Force groups, including a Task Force to investigate the impact of allergy on adolescents. She is also the Chair of the Psychology Working Group for the British Society for Allergy and Clinical Immunology. Currently she is looking at psychological predictors of effective allergy management and psychological service needs of patients and families across the UK, Europe and North America.

Katherine KnightChildren’s Allergy Clinical Nurse Specialist, St Thomas’ Hospital, London, UK

Katherine has worked as a Clinical Nurse Specialist at the St Thomas’ Hospital Children’s Allergy Service since 2013. She is the immunotherapy lead for the service and specialises in allergic rhinitis, omalizumab

therapy for severe asthma and food allergy. Katherine teaches on various allergy study days and leads on the community allergy training sessions. She is co- director of the Allergy Academy Allergy in Practice course and has presented at past BSACI and PAAM conferences. She has recently completed and obtained an allergy masters from Southampton University and submitted a dissertation regarding the adrenaline auto injector prescribing practice of the St Thomas’s allergy team. Katherine is very proud of the multidisciplinary approach to allergy as well as the strong nurse led services within the children’s allergy service at St Thomas’s and is keen to share her allergy knowledge and experience.

69wao-bsaci.org

Dr Susan LeechConsultant Paediatric Allergist, Kings College Hospital NHS Foundation Trust, UK

Susan is a paediatric allergist and clinical lead at Kings College Hospital London. She qualified from Cambridge University and trained in paediatrics at Southampton and Kings, London. She trained in paediatric

allergy and immunology at Oxford and Kings College London, where she completed an MSc in medical immunology. She is clinical lead for the paediatric allergy service at Kings College Hospital and leads the South Thames Allergy Network. She is treasurer and Trustee of the British Society for Allergy and Clinical Immunology. She has been the allergy training advisor for the RCPCH CSAC and was a founder member and chair of the Paediatric allergy committee of the BSACI. As a member of the BSACI Standards of Care Committee she has co-authored national guidelines on rhinitis, adrenaline autoinjectors, penicillin allergy, chronic urticaria and angioedema, immunotherapy, bee and wasp venom allergy and egg allergy. She is the UK delegate to the European Training Committee for Paediatric Allergology.

Professor Andreas LopataProfessor in Biochemistry, James Cook University, Australia

Professor Lopata is a molecular immunologist and Professorial Chair with the Department of Molecular & Cell Biology at the James Cook University, and the Tropical Futures Institute at James Cook University-Singapore. He

graduated from the Henrich Heine University (Germany), completed his postgraduate studies in medical sciences at the University of Cape Town (South Africa) and worked in the Institute of Infectious Disease and Molecular Medicine before relocating to Australia. His research team uses cutting-edge molecular and cellular approaches in characterising the interactions of immunogenic proteins from different food sources with the human immune system, leading to allergic and inflammatory reactions. The outcomes of his research translate into the development of novel diagnostics, detection systems for contaminated food products and platform knowledge for immunotherapeutics. He is Regional Associate Editor (Asia Pacific) for the World Allergy Association Journal (WAO), Frontier Allergy, Foods and on the editorial board of Clinical & Experimental Allergy, Proteomes and Molecular Immunology. He is active committee member within the World Allergy Organisation, WAO-International Union of Immunological Societies and the Australasian Society of Clinical Immunology and Allergy.


Professor Bryan Martin Chief of Allergy Immunology, Ohio State University, US

Professor Bryan Martin has served at many roles at The Ohio State University, where he has been Associate Dean for Graduate Medical Education, the Designated Institutional Official, Associate Medical

Director of University Hospital and Chief of Allergy and Immunology. Prior to joining the faculty at Ohio State, Dr. Martin spent 29 years in the United States Army, where he was the Chair of the Department of Allergy and Immunology at the Walter Reed Army Medical Centre, Program Director of the Allergy Immunology Fellowship and the Consultant to the Army Surgeon General for Allergy and Immunology. Active in Organized Medicine at all levels, Dr. Martin is the President-Elect of the World Allergy Organization, Past President of the American College of Allergy, Asthma and Immunology (ACAAI), and Past Chair of the International Collaboration in Asthma, Allergy and Immunology (iCAALL). A Distinguished Fellow of the ACAAI, Dr. Martin is the recipient of a number of national awards, to include the Accreditation Council for Graduate Medical Education Parker J. Palmer “Courage to Teach” Award for innovative teaching and health care as a program director and the Lewis Aspey Mologne Award, the Army Surgeon General’s Award for Military Academic Excellence.

Tim McLachlan Chief Executive, The Natasha Allergy Research Foundation

Tim McLachlan is Chief Executive of The Natasha Allergy Research Foundation, responsible for the strategic direction and all the Foundation’s activities across the UK and globally. The vision of Natasha’s

Foundation is to make allergy history through preventing and eradicating allergic disease, creating a world without allergy. As the only charity in the UK dedicated to funding allergy research, the Foundation also campaigns to change policy, including Natasha’s Law (implemented October 2021) and calling for an Allergy Tsar (July 2021) as well as raising awareness. As Chief Executive, Tim also oversees the Foundation’s developing portfolio of pioneering research into the treatment, prevention and causes of food allergy. Tim has worked in the voluntary sector for over 20 years leading and developing national charities in health and social care, Olympic Legacy and social exclusion. Tim completed an MBA at the University of Liverpool, their first student to do so focussing on the voluntary sector. His first degree was in Medicinal Chemistry at the University of Newcastle upon Tyne where he specialised in cancer chemotherapy and the treatment of infectious diseases. Away from work Tim enjoys Cathedral Choral Music, leading Explorer Scouts (including the Duke of Edinburgh Award) and hill walking with one or more of his four rescue sighthounds.

71wao-bsaci.org

Dr Rosan Meyer Visiting Professor, Winchester University, UK

Rosan completed her degree in dietetics in South Africa in 1996 and finished her MSc in 2004 and PhD at Imperial College London in 2008. She was the principal research dietitian at Great Ormond Street Hospital until

December 2015, and after this worked with the allergy team at St. Thomas Hospital until 2018. She has a busy paediatric dietetic practice in London and has published numerous articles and books. She is currently module leader for the Food Hypersensitivity Module of the MSc in Allergy at Imperial College and is visiting Professor at KU Leuven, on their MSc on Deglutology and University of Winchester on their anthropometry and ARFID module. She is also the secretary for the EAACI Allied Health and Primary Section and chair of the task force working on non-IgE mediated allergy and feeding difficulties.

Dr Louise MichaelisConsultant Paediatrician in Immunology and Allergy, Great North Children’s Hospital, UK

Dr Louise Michaelis is a Consultant Paediatrician and a Senior Lecturer in Immunology and Allergy at The Great North Children’s Hospital Newcastle upon Tyne and Population Health Sciences, Newcastle

University. Dr Michaelis co-ordinates NIHR/MCRN Portfolio clinical trials which focus on immune and inflammatory mechanisms of tolerance in multi-system allergy in childhood. Awards include “NIHR Leading Principle Investigators Award-2016”, “NIHR NENC Commercial Team award- 2017”, and runner up for Educational Research Supervisor of the Year Newcastle University - 2020. She participates in undergraduate and postgraduate teaching forums as part of Faculty for the Allergy eModule at Newcastle University and the Allergy MSc Course at The University ofSouthampton. Dr Michaelis works within a busy Tertiary Paediatric Allergy Service leading on drug allergy (desensitisation), Targeted Therapies and biologics for children with severe Th2 allergic inflammatory disease. She is the Chief Investigator of the ‘Model of Seamless Allergy Care in Children’ achieving two Bright Ideas in Health Awards for Service Improvement (2017) and as part of the RCPCH Sepsis Podcasts ‘Drugs and Bugs’ (2019).


Dr Josh Milner Columbia University Irving Medical College, USA

Dr. Joshua Milner is a Professor of Pediatrics in the Institute of Genomic Medicine and the Director of Allergy/Immunology and Rheumatology at Columbia University Irving Medical Center. His research centers around the genetics and immunopathology of inborn disorders of the

immune system, with the ultimate goal of identifying pathways relevant for diagnosis and treatment of both rare and common allergic and immunologic diseases. His particular focus is on monogenic causes of allergic disease, a class of disorders now referred to as “Primary Atopic Disorders.” Previously, he was the Chief of the Laboratory of Allergic Diseases in the NIAID intramural research program at the NIH. Dr. Milner earned a bachelor’s degree in biology from the Massachusetts Institute of Technology in 1995 and a medical degree from the Albert Einstein College of Medicine in 2000, with special distinction in immunology. He completed a residency in pediatrics at Children’s National Medical Center in Washington, D.C., followed by a fellowship in allergy and immunology at NIAID with the late William E. Paul. Dr. Milner is board-certified in allergy and immunology. He has been elected to the American Society for Clinical Investigation, the Association of American Physicians, and the Henry Kunkel Society. He has received several NIH Director’s Awards, the 2015 Phadia Allergy Research Forum Award, the 2017 Gale and Ira Drukier Prize in children’s health research, the Society for Pediatric Research’s 2019 E. Mead Johnson Award and the 2021 American Academy of Allergy Asthma and Immunology Foundation Heritage Lectureship. He has published more than 140 papers and has served on the editorial boards of multiple journals.

Dr Antonella Muraro Consultant allergist and pediatrician, Head of the Food Allergy Referral Centre, Padua University hospital Padua, Italy

Dr. Muraro is a Consultant allergist and pediatrician, Head of the Food Allergy Referral Centre at the Padua University hospital in Padua, Italy. She is Past President of the European Academy of Allergy and Clinical

immunology -EAACI. During her term at EAACI she chaired the first Food Allergy and Anaphylaxis Guidelines 2014 and Update 2021 as well as the Allergen Immunotherapy Guidelines 2017-2018 . She is currently member of the Executive Committee of the Global Allergy and Asthma Network of Centres of Excellence -GA2LEN and of the Steering Committee of the Food Allergy & Anaphylaxis -ANACare Network of Centres. She has authored more that 260 articles and book chapters being awarded as Highly Cited researcher in 2021 and 2022 by the Web Science Clarivate analytics. She is Professor of food allergy at Padua School of Medicine. At the Food Allergy Centre she has implemented a multidisciplinary and multi-professional approach to the diagnosis and treatment of allergic diseases integrating allergist, pediatrician, dietitian , a dedicated psychologist focusing on education and training of patients, school staff and restaurant. Her research aims to evaluate biomarkers for severe food reactions as well as innovative treatments for food allergy and pediatric allergy.

73wao-bsaci.org

Dr Mário Morais-AlmeidaHead, Immunoallergy Department, CUF-Descobertas Hospital and CUF-Infante Santo Hospital, Lisbon, Portugal

Mário Morais-Almeida is the Head of the Immunoallergy Department of CUF-Descobertas Hospital (World Allergy Organization Center of

Excellence) and CUF-Infante Santo Hospital, Lisbon, since 2003; apart the supervision of the department activities, he dedicates more than twenty hours per week to clinical activity in the out-patient section of the Allergy Center. He graduated from the Lisbon School of Medicine in 1986 and became Specialist in Allergy and Immunology in 1994 and senior consultant since 2002, being also specialist in in Health Units Management since 2003. Dr. Morais-Almeida has a Master in Respiratory Diseases and recently submitted a PhD thesis to NOVA Medical School in Lisbon. He is a collaborator of the Center for Health Technology and Services Research, Oporto Faculty of Medicine, since 2012. He is currently the president of the Portuguese Association of Asthmatic Patients (2016-2019), and served as president of the Portuguese Society of Allergy and Clinical Immunology (2005-2013), the Allergy and Clinical Immunology Board of the Portuguese Medical Association (2003-2006), the Luso-Brazilian Society of Allergy and Clinical Immunology (2009-2010), the South European Allergy Societies (2011), and vice president of the Latin American Allergy, Asthma and Immunology Society (2013-2015) and of the Lung Portuguese Foundation (2010-2012). He served on government and nongovernmental committees, namely the National Observatory on Respiratory Diseases, GINA and ARIA initiatives and the National Commission of Asthma, being a regular Consultant of several Portuguese Ministry of Health Departments since 1996. He is co-coordinator of the Portuguese guidelines on Asthma management and Anaphylaxis registration, management and referral, being member of the work group responsible for the Portuguese Catalog of Allergies and Adverse Reactions.

Professor Liam O'MahonyImmunologist,University College Cork, Ireland

Professor Liam O’Mahony received his BSc in Microbiology from University College Cork, Ireland in 1994 and his PhD in Immunology was awarded in 1998 by Trinity College Dublin, Ireland. Thereafter, Prof.

O’Mahony performed post-doctoral research at the Department of Microbiology, University College Cork, Department of Medicine, University College Cork and the Digestive Diseases Division, UCLA. Dr. O’Mahony was a Principal Investigator at the Alimentary Pharmabiotic Centre, University College Cork, from 2003 to 2008. From 2009 to 2018, he was head of Molecular Immunology at the Swiss Institute of Allergy and Asthma Research, University of Zürich, Switzerland. He is currently the Prof. of Immunology at the Departments of Medicine and Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland. He is also currently the EAACI Treasurer and is an Allergy associate editor. His research interests are focused on the molecular basis for microbe and metabolite modulation of mucosal inflammatory responses. In particular, Prof. O’Mahony is investigating the basic mechanisms by which microbes influence allergic sensitization within the gut, skin and lungs.


Professor Nikolaos PapadopoulosProfessor of Allergy, University of Athens, Greece

Nikolaos (Nikos) Papadopoulos’ work focuses on the role of infection and its interaction with atopy, as keystone events of respiratory allergy pathophysiology as well as targets for treatment. In the course of this

career, he has identified some of the key mechanisms leading from common viral exposures to asthma exacerbations and persistence. He is Professor and Head of the Allergy Department, 2nd Pediatric Clinic, University of Athens; also Honorary Professor at the University of Manchester and at OPRI, Singapore. He has supervised more than 20 PhDs, organized over 100 educational events and has trained doctors in the clinic and researchers in the lab. He is invited speaker at international events more than 30 times a year. He has participated and led several high-impact EU research projects from FP5 all the way to Horizon2020. He has actively served many international societies, most notably EAACI (President 2013-2015) and the Respiratory Effectiveness Group (REG, President 2018-2020). He has received several international awards, among other, the EAACI Clemens von Pirquet Award (2019), the PhARF award (2010), the Klosterfrau International Award for Research in Pediatric Asthma (2003) and the ERS Annual Award for Pediatric Respiratory Research in Europe (2004). He has published over 500 papers, receiving more than 45000 citations and an h-index of 96 (Google Scholar). He is Editor-in-Chief of Frontiers in Allergy and Associate Editor of Clinical & Translational Allergy. Currently he is exploring the role of the respiratory virome in asthma, evaluating potential interventions against rhinoviruses using microRNAs, while he is leading PeARL (Pediatric Asthma in Real-Life), a think tank that aims to optimise pediatric asthma management.

Dr Manish PareekAssociate Clinical Professor, University of Leicester, UK

Dr Manish Pareek graduated from the University of Birmingham with Honours in Medicine and undertook general medical training before completing an academic specialist training programme in Infectious

Diseases and General Medicine in Leicester and London (Imperial College London) funded by the NIHR and MRC. At present he is an Associate Clinical Professor at the University of Leicester and Honorary Consultant in Infectious Diseases within University Hospitals of Leicester. His primary research interests are: tuberculosis, migrant health, health policy, modelling and health economics. He has undertaken a significant amount of work on the impact of ethnicity on COVID-19 outcomes and is the Chief Investigator of UK-REACH which is examining COVID-19 in healthcare workers.

75wao-bsaci.org

Kelly ParkerPaediatric Allergy Nurse Specialist / Matron, The Princess Alexandra Hospital, UK

Kelly Parker is the Paediatric Allergy Clinical Nurse Specialist / Matron at The Princess Alexandra NHS Trust where she continues to implement nurse-led services within allergy, prior to this post she was the

Paediatric Allergy Clinical Nurse Specialist at East and North Herts NHS Trust where she established the nurse-led services within the Allergy Department including a nurse-led eczema clinic which is her particular area of interest. Kelly has a keen focus on driving forward Nurse-led services. Kelly also participates in allergy training days for local GP’s.

Dr David PedenDistinguished Professor of Pediatrics and Senior Associate Dean for Translational Research, University of North Carolina School of Medicine, USA

Dr. David B. Peden is the Harry S. Andrews Professor of Pediatrics, Medicine and Microbiology/Immunology as serves as the Senior

Associate Dean for Translational Research and Medical Director, Center for Environmental Medicine, Asthma & Lung Biology for the UNC School of Medicine (SOM). Dr. Peden is currently principal investigator for over $5 million of federally grant funded research from the US Department of Defense, EPA, NHLBI, NIAID, and NIEHS. His research program focuses on assessing human inflammatory response to ozone, endotoxin, concentrated air particulates and woodsmoke particles, identifying biological determinants of response, and testing interventions to mitigate these effects and for treatment of airway disease. Dr. Peden is also a member of the World Allergy Organization Board of Directors, past president of the American Academy of Allergy, Asthma and Immunology, Editor-in-Chief of the Journal of Allergy and Clinical Immunology: Global, and Chair of the FDA Allergenic Products Advisory Committee. He is certified in pediatrics, allergy and immunology and clinical laboratory immunology.

Professor Graham RobertsProfessor and Consultant in Paediatric Allergy and Respiratory Medicine, University of Southampton, UK

Graham Roberts is a Professor and Consultant in paediatric allergy and respiratory medicine at University of Southampton and University Hospital Southampton NHS Foundation Trust. He is also the Co- Director

of the David Hide Asthma and Allergy Research Centre on the Isle of Wight. Professor Roberts is President of the British Society of Allergy and Clinical Immunology. He Chairs the European Academy of Allergy and Clinical Immunology Adolescent and Young Adult Task Force.


Dr Hugh SampsonProfessor of Pediatrics, Icahn School of Medicine at Mount Sinai and Jaffe Food Allergy Institute, USA

Dr. Hugh A. Sampson is the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine in New York and has over 40 years’ experience

in translational research focusing on food allergic disorders and basic immunologic mechanisms responsible for these disorders. He has authored/co-authored over 530 original articles and 90 book chapters, and co-edited 5 books, primarily on clinical and immunopathogenic aspects of food allergic disorders, and chaired working groups that produced standardized criteria for diagnosing anaphylaxis (NIAID/FAAN Guidelines on Anaphylaxis) and conducting double-blind placebo-controlled oral food challenges (Practall Guidelines). Dr. Sampson was elected to membership in the National Academy of Medicine of the National Academies in 2003 for his research accomplishments. He is the past-president of the American Academy of Asthma, Allergy & Immunology, past Chairman of the Section on Allergy & Immunology of the American Academy of Pediatrics, past Board member of the World Allergy Organization, and has served on the Editorial Boards of five allergy journals. Dr. Sampson also has trained over 40 post-doctoral allergy/immunology fellows, many of whom are now leaders in the field of food allergy.

Professor Alexandra SantosProfessor of Paediatric Allergy and Honorary Consultant in Paediatric Allergy, King’s College London and Evelina London Children’s Hospital, UK

Professor Alexandra Santos is Professor of Paediatric Allergy at King’s College London and Honorary Consultant in Paediatric Allergy at the Evelina London Children’s Hospital. Alexandra qualified in Medicine from

the University of Coimbra and completed her PhD in Allergy and Immunology at King’s College London, supervised by Professor Gideon Lack. Over the years, Alexandra has continued to combine clinical activity in Paediatric Allergy with clinical and laboratory translational research into food allergy. The Santos Lab aims to improve the accuracy and safety of food allergy diagnosis and our understanding of the mechanisms of food allergy and oral tolerance in IgE-sensitised children in order to identify new targets for definitive treatment of food allergy. Alexandra has received prestigious awards from the Medical Research Council (MRC): an MRC Clinical Research Training Fellowship, an MRC Centenary Early Career Award, the MRC Clinician Scientist Fellowship and MRC Transition Fellowship. She has also obtained funding from the NIH for her work in the LEAP Study, from Food Allergy Research and Education (FARE) and from Asthma UK as Principal Investigator of Asthma UK Centre in Allergic Mechanisms of Asthma. Alexandra is the Chair of the Board of the Food Allergy Interest Group of European Academy of Allergy and Clinical Immunology (EAACI) and of the upcoming EAACI Food Allergy Guidelines.

77wao-bsaci.org

Professor Jürgen SchwarzeEdward Clark Chair of Child Life and Health, Institute for Regeneration and Repair, Centre for Inflammation Research, University of Edinburgh

Professor Schwarze (FRCPCH) is the Edward Clark Chair of Child Life and Health at the University of Edinburgh, a paediatrician specialised in

allergy and respiratory medicine, and an internationally recognised expert in immune mechanisms of RSV bronchiolitis and associated airway allergy. Dr Schwarze qualified in Medicine from Freiburg University, Germany in 1988, trained as a paediatrician specialising in paediatric respiratory medicine and paediatric allergy and he now leads the paediatric allergy service at the Royal Hospital for Sick Children Edinburgh and has been the clinical lead for the national Children's and Young People's Allergy Network Scotland (2011 -2019). In 1994, as a post-doctoral fellow at National Jewish Medical and Research Centre in Denver, Colorado, Dr Schwarze started to work on immune responses in RSV bronchiolitis and allergic airway disease. He continued his research at the Ruhr-University Bochum, Germany, and from 2002 to 2007 at Imperial College London where, as a Wellcome Trust Senior Fellow, he focused his research on the role of lung dendritic cells in respiratory viral infections and subsequent reactive airway disease. In 2007 he moved to the Centre for Inflammation Research at the University of Edinburgh and took up his current Chair in 2008. Professor Schwarze's research programme aims to understand mechanisms of inflammation at the interface of innate and adaptive immunity in respiratory viral infections to help develop urgently required treatments for viral bronchiolitis in infants and virus driven asthma exacerbations. He uses both pre-clinical models and clinical samples to investigate the roles of lung dendritic cells and airway epithelial cells in the induction, maintenance and resolution of virus induced immune responses and inflammation in the lung.

Melissa SinghPsychological Well-being Practitioner, Anaphylaxis Campaign, UK

Melissa Singh currently works for the NHS and has recently finished her studies at University College London, qualifying in Cognitive Behavioural Therapies managing a caseload of 40+ clients with anxiety

and depression. Following her personal experience with anaphylaxis and allergy management, she now works collaboratively with the Anaphylaxis Campaign. Her sister, Samantha Singh sadly passed away from anaphylaxis in July 2020 at the age of 26. Melissa observed the inquest investigations leading to the publication of the Prevention of Future Deaths Report which identified significant learning points for Healthcare Professionals which she wants to explore in the conference. Having experienced the tragic loss of her sister to anaphylaxis, she hopes to encourage confidence in speaking up about allergies and further for Healthcare Professionals to empower people with and people supporting those with allergies to speak up.


Dr Isabel SkypalaConsultant Allergy Dietitian, Royal Brompton & Harefield, UK

Dr Isabel Skypala is a Consultant Allergy Dietitian at the Royal Brompton & Harefield Hospitals (RBHT), and the clinical lead for the adult food allergy service. She is also an honorary Senior Clinical Lecturer at Imperial

College London and co-leads the Food Allergy module of the Allergy MSc. Isabel lectures at international level and has authored many peer-reviewed papers and books. Her research has primarily been focussed on plant food allergy in adults, including Pollen Food Syndrome and Lipid Transfer Protein Allergy. She has promoted the role of dietitians in allergy, establishing the Food Allergy Specialist Group of the British Dietetic Association and co-founding the International Network of Diet and Nutrition in Allergy, now allied to the American Academy of Allergy, Asthma & Immunology (AAAAI). Isabel was the first dietitian to sit on both the Council of the British Society of Allergy & Clinical Immunology (BSACI), and the Executive Committee of the European Academy of Allergy & Clinical Immunology. In 2014, Isabel received the BSACI William Frankland award for services to clinical allergy, and the AAAAI Allied Health Professional of the year award in 2022.

Gunter SturmAssociate Professor, Medical University of Graz, Graz, and Head, Allergy Outpatient Clinic Reumannplatz, Vienna, Austria

Gunter Sturm is head of the Allergy Outpatient Clinic Reumannplatz in Vienna and Associate Professor at the Department of Dermatology

and Venerology, Medical University of Graz in Austria. He is first author of the EAACI guidelines on Hymenoptera venom immunotherapy and is currently chair of the EAACI working group Insect Venom Hypersensitivity. He and his research group focuses on diagnosis and treatment of insect venom allergy since more than 20 years.

Dr James L. SublettClinical Professor, University of Louisville School of Medicine, USA

James L. Sublett, MD, FACAAI, FAAAAI serves on the Board of Directors of the World Allergy Organization. He is a Past President (2014-2015) of the American College of Allergy, Asthma & Immunology (ACAAI) and

currently serves as the ACAAI’s Executive Director for Advocacy and Governmental Affairs. He has been honored by the College as a Distinguished Fellow. He is a Clinical Professor at the University of Louisville (UofL) School of Medicine and for over twenty years served as the Section Chief. He is the co-founder of Family Allergy & Asthma, which is one of the largest allergy & immunology practices in the United States, with sixty-five board certified allergists/immunologists serving eighty clinics in six states. Dr. Sublett also sits on several other boards, including the UofL President’s Advisory Council and the Norton Healthcare Board of Trustees. He received his MD degree from UofL and completed a residency in Pediatrics and a Fellowship in Allergy and Immunology in the Department of Pediatrics, Children’s Hospital, UofL School of Medicine. Sublett is regarded as an expert on the effects of air pollution on human health, especially related to indoor environments. He is married and lives with his wife, Lelia, in Anchorage, KY.

79wao-bsaci.org

Professor Mamidipudi Thirumala KrishnaUniversity Hospitals Birmingham NHS Foundation Trust and University of Birmingham

Professor Thirumala Krishna (TK) is Consultant Allergist and Immunologist at University Hospitals Birmingham (UHB), Honorary Professor in Allergy, Clinical Immunology and Global Health at University of Birmingham (UoB)

and Head of Postgraduate School of Pathology at West Midlands Health Education England. His research programme involves a combination of clinical, epidemiological and laboratory methodology as well as an integrated mixed methods approach in multiple aspects of Allergy and Asthma in the UK and Low-Middle Income Countries. He has received funding from multiple UK funding bodies including MRC CiC, NIHR, FSA and GCRF. TK is lead author of the BSACI venom allergy guideline and co-authored allergen-specific immunotherapy for allergic rhinitis, penicillin allergy and pollen-food syndrome guidelines. He served as Clinical Lead for IQAS (Royal College of Physicians national accreditation program for Allergy; 2015-21), steering group member of BRIT registry (2020-21) and is currently Chair of BSACI Equality, Diversity and Inclusion working group. He is an associate editor for Clinical Experimental allergy. TK led a successful application for UHB and UoB in 2020 to be designated as a World Allergy Organization Centre of Excellence in Allergy, Asthma and Clinical Immunology. He was awarded the prestigious Jack Pepys lectureship in 2021 by the BSACI.

Dr Peter Valentin TomazicENT Specialist, Medical University of Graz, Austria

Dr. Tomazic graduated from the Medical University Graz in 2008. After being research fellow for 6 months, he became resident at the ENT-University Hospital Graz, Department of General ORL Head and Neck

Surgery, where he is active since May 2009. He started his PhD-studies in 2011 focusing on proteomic analysis of nasal mucus in allergic rhinitis. He was promoted to Assistant Professor in 2014. In December 2016 he finished his PhD and became Associate Professor in March 2017. He is member of the interdisciplinary Skull Base Group at the Medical University of Graz.

Professor Sanna Toppila-SalmiSenior Consultant Otorhinolaryngologist, Skin and Allergy Hospital of the Helsinki University Hospital & University of Helsinki, Finland

Sanna Toppila-Salmi, MD, PhD, Adj. Prof. is a Senior Consultant Otorhinolaryngologist, Department Chief Physician and Director of

Helsinki Airway Research Group at the Skin and Allergy Hospital of the Helsinki University Hospital & University of Helsinki. Her research group combines epidemiology, genomics, metabolomics and sequence analysis to identify pathobiology of asthma, CRSwNP, NERD, Type 2 inflammation and allergic diseases. Her lab works with human cohorts to identify risk factors, mechanisms, and potential therapies for these disorders using machine learning data science, sequencing omics approaches and clinical trials . Dr. Toppila-Salmi is Associate Editor of Clinical and Translational Allergy, and Editorial Board Member and Reviewer in several Scientific Journals such as Am J Respir Crit Care Med, BMC Medical Genetics, BMJ Open, JACI and Scientific Reports. She is the secretary of ENT section of EAACI.


Dr Paul TurnerReader in Paediatric Allergy & Clinical Immunology, Imperial College London, UK

Dr Paul Turner is a Reader / Clinician Scientist and Honorary Consultant in Paediatric Allergy & Immunology at Imperial College London, and Clinical Associate Professor at the University of Sydney, Australia. His research,

funded by the Medical Research Council, European Commission, NIHR and UK Food Standards Agency among others, focusses on the pathophysiology of severe allergic reactions to food. He is a member of the UK Food Standards Agency's Science Council, the FAO/WHO Codex Expert Consultation on Risk Assessment of Food Allergens and leads the EAACI Taskforce on Food Allergen Thresholds. Paul leads the food allergy desensitisation programme at St Mary's Hospital, London; the team was awarded the Best UK Clinical Team by Allergy UK in 2018. Paul was also the recipient of the 2020 PhARf Award, awarded by the European Academy of Allergy and Clinical Immunology (EAACI). He is a consultant to Public Health England, and Chairperson of the WAO Anaphylaxis Committee and emeritus chair of the BSACI Paediatric Allergy Committee.

Professor Ronald van ReeProfessor of Molecular and Translational Allergology, Amsterdam University Medical Centers, The Netherlands

Ronald van Ree is Professor of Molecular and Translational Allergology at the Department of Experimental Immunology and the Department of Otorhinolaryngology of Amsterdam University Medical Centers, location

AMC, in The Netherlands. His research group focuses on elucidating the mechanisms of allergic sensitization and the role of allergen structure and exogenous environmental, microbial and dietary factors in this process. Epidemiology of food allergy, in and outside Europe, has been at the center of his attention for the last two decades. Other areas of attention are component-resolved diagnosis, allergen standardization of diagnostic and therapeutic allergen products, and the development of innovative AIT approaches for the treatment of respiratory and food allergies, using recombinant and nano-technologies and novel adjuvants.

Amena Warner, Head of Clinical Services, RN. SN. (PG Dip) Specialist Practice. Dip Allergy.Allergy UK

Amena is Head of Clinical Services at Allergy UK a national patient charity that works to raise awareness of allergic disease both nationally and internationally. She took up this appointment after working as a Clinical

Nurse Specialist in Immunology and Allergy at an NHS Hospital Trust. She trained at University College Hospital, followed by paediatric training at Great Ormond Street Hospital in London. She also holds a Public Health and Specialist Practice in School Nursing qualification gained in 1994. Visiting schools and carrying out health assessments made Amena very aware of the rising incidence of allergy in the UK and was instrumental in developing her interest in the field. Amena is a member of the Immunology & Allergy Nurses group and is the first nurse to sit on the British Society of Allergy & Clinical Immunology (BSACI) council where she started the National Nurses in Allergy Group. She is a member of the BSACI Primary Care group and also the BSACI Adult Allergy group.

81wao-bsaci.org

Professor John WarnerEmeritus Professor of Paediatrics, Imperial College, London, UK

John O. Warner OBE MD FRCP FRCPCH FMedSci FERS is Emeritus Professor, National Heart and Lung Institute, Imperial College, London and Hon. Professor Paediatrics University of Cape Town. Previously he

was Professor of Paediatrics Imperial College 2006-2019 and Professor of Child Health University of Southampton 1990-2006. He had over 500 publications in medical journals. His past appointments have included being; Head Paediatric assembly, European Respiratory Society (1993-7); Editor in Chief, Pediatric Allergy and Immunology 1998-2010; and President Academic Paediatric Association (GB and I) 2009-2014. He has received the following awards; BSACI William Frankland award (2005); Pepys and Morrow Brown lectures (2011, 2014); Lifetime Achievement award European Respiratory Society (2009); and OBE for services to food allergy research (2013). His research interests focus on; Inhalant and food allergy; Allergy prevention; Asthma; Mechanisms of airway inflammation; Developmental origins of Health and Disease; Integrated care pathways for long term conditions; and Paediatric long-COVID.

Simon WilliamsChief Executive Officer, Anaphylaxis Campaign, UK

Simon joined as Chief Executive in November 2021 having previously been Head of External Affairs at HEART UK The Cholesterol Charity. Simon led successful campaigns for better services and access to medicines for

people with heart disease, as well as playing a leading role in transforming the charity’s communications, commercial partnerships and income generation. As the new Chief Executive, Simon is committed to extending the support and reach of the charity and transform its approach to helping many more people.


Professor Gary WongProfessor, Department of Paediatrics and School of Public Health, The Chinese University of Hong Kong

Gary WK Wong is Professor, Department of Paediatrics and School of Public Health, The Chinese University of Hong Kong, where he has been working for 20 years. He is a member of the World Allergy Organization

(WAO) Board of Directors, an assembly member of the Global Initiative for Asthma (GINA), a steering committee member of the International Study of Asthma and Allergies in Childhood (ISAAC) research group, and Past President of the Asia-Pacific Association of Pediatric Allergy, Respirology and Immunology (APAPARI). Dr. Wong also participates actively in paediatric and medical communities in Hong Kong. He is current Council member of the Hong Kong Society of Respirology (HKSPR) and Chair of the Asthma Focus Group of the HKSPR. Dr. Wong obtained his undergraduate medical education from the University of Alberta, Canada. He subsequently received fellowship training at University of British Columbia, and Children’s Hospital of British Columbia and visiting Fellowship at the Children’s Hospital at Munich, Germany. He was a research fellow in 2001 at the Children’s Hospital in Munich. Dr. Wong has strong interest in different aspects of allergic and autoimmune diseases. His main research interests are treatment, prevention, and control of allergic conditions including asthma, childhood wheezing disorders, and food allergies. In particular, he is interested the immunological and environmental determinants of asthma and related allergic disorders. He has published over 280 original articles, review papers, and book chapters in the field of asthma and related atopic conditions. Among other duties within several editorial boards, Dr. Wong is Associate Editor of New England Journal of Medicine, board member of Pediatric Allergy and Immunology, and Chief Editor of Pediatric Respirology and Critical Care Medicine.

Karen WrightAllergy research Dietician, King’s College London, UK Paediatric Allergy Research, Department of Women and Children’s Health & School of Life Course Sciences Evelina London Children’s Hospital, Guy's and St Thomas' NHS Foundation Trust Children's Allergy Service, UK

Karen is an allergy dietitian and worked for many years in allergy in Singapore. Since returning to the UK she has worked as an allergy specialist dietitian in Southampton and in London, where she is currently working in allergy research. Karen is Co-Chair of the British Dietetic Association Food Allergy Specialist Group and a member of the British Society of Allergy and Immunology Allergy Education Network (BAEN) project which aims to guide strategic developments around allergy education. In 2021 Karen was awarded the British Society of Allergy and Clinical Immunology Anthony Frew Award for Excellence in Education.

83wao-bsaci.org

Dr Kiwako Yamamoto-HanadaChief, Allergy Center, National Center for Child Health and Development, Japan

Kiwako Yamamoto-Hanada, MD, Ph.D. is Chief of Allergy Center and team leader of Medical Support Center of Japan Environment and Children’s Study at National Center for Child Health and Development

(National Children’s Hospital) in Tokyo, Japan. She graduated from the University of Yamaguchi School of Medicine, Yamaguchi, Japan in 2003 (MD degree). She obtained her Ph.D. degree at the Department of Health and Psychosocial Medicine, Aichi Medical School, Aichi, Japan in 2016. She is the board-certified pediatrician (faculty of Japan Pediatric Society) and board-certified allergist (faculty of Japanese Society of Allergology). She is a member of the Allergy Prevention Committee of WAO. Her research interests are epidemiology, allergy prevention, and environmental health. She has published about 100 peer-reviewed articles. Detailed publications are at https://orcid.org/0000-0003-1288-9620.

Dr Anahí YáñezMedical Doctor, Research Center in Allergy and Respiratory Disease – InAER, Argentina

Anahi Yañez is an Allergy and Immunology Specialist , Medical Director and Principal Investigator of InAER: Research Center for Allergy and Respiratory Diseases, in Buenos Aires, Argentina, since 2006. She

graduated in 1982 from Universidad Nacional del Nordeste (UNNE), School of Medicine, and became Specialist in Allergy and Immunology. She works in Clinical Research in Research Center for Allergy and Respiratory Diseases since 2009. She has authored several articles in international publications. She has served as President of Asociacion de Alergia, Asma e Inmunologia Clinica (Argentina). She has been part of many other allergy and asthma associations. Currently she is a member of the Asthma Committee of the World Allergy Organization (WAO), she is WAOBiologics for Adult Severe Asthma Chair, and SLAAI Asthma Committee Chair .She is part of the Editorial Board of Asthma Research and Practice, and Editor at Large of the World Allergy Organization Journal. Dr. Yañez has been elected as Member at Large to the WAO Board of Directors, for a four years term, starting in January 2018.


Working with our Industry PartnersThe BSACI Conference aims to develop best practice care for patients with allergic disease through education and research. BSACI has a pivotal role in maintaining high quality support for allergy professionals therefore our conference should always highlight best quality practice, promote expertise and current science available in our field, whilst at the same time being accessible amongst all multi-disciplinary professionals across the UK and beyond. The relationship BSACI has with our industry partners brings many benefits to our patients of which we are all aligned on. We thank our industry partners for supporting the conference and scientific exchange.

BSACI ensures the development of the programme is not influenced by industry and that financial support does not constitute an inducement to health professionals or any other relevant decision makers to prescribe, supply, recommend, buy or sell any medicine. The programme framework has been developed around our educational content whilst allowing time for our delegates to interact with our industry partners.

The Programme Planning Committee consists only of multidisciplinary healthcare professionals whose areas of expertise are represented throughout the programme. They are expected to uphold the professional standards outlined by the General Medical Council or their own profession's regulatory guidance and to follow the BSACI's industry policy.

The BSACI expects all speakers to declare all relevant commercial conflicts of interest that have been received within the preceding 36 months at the start of their presentation. Industry symposia are run within the conference and are clearly branded and listed separately from the main scientific programme. Industry representatives are not permitted to present on the main study programme. Industry promotional activities take place only within the Exhibition Hall where delegates are able to find out more about the benefits for patients through research and development opportunities, new product investigation as well as gain vital scientific knowledge and to be at the forefront of breakthrough treatments which will be of benefit to patients and the public.

85wao-bsaci.org

The BSACI’s interactions with the commercial sector are transparent and ethical, in compliance with current guidance as provided by:

l The Medicines and Healthcare products Regulatory Agency’s ‘Blue Guide’l The Prescription Medicines Code of Practice Authority (PMCPA) guidance which

administers the Association of the British Pharmaceutical Industry’s (ABPI’s) Code of Practice for the Pharmaceutical Industry

l Best Practice Guidance on joint working between the NHS and pharmaceutical industry and other relevant commercial organisations – NHS - Prepared by:Medicines, Pharmacy and Industry Group

l Financial and commercial arrangements and conflicts of interest, General Medical Council

l International Committee of Medical Journal Editors guidance (ICMJE)l General Data Personal Protection (GDPR)l Code of Conduct; Code of Accountability in the NHSl European Federation of Pharmaceutical Industries and Associations code on the

promotion of prescription-only medicine to, and interactions with, healthcare professionals (EFPIA)

l The Association of British HealthTech Industries Code of Business Practice (ABHI)l MedTech Europe Code of Ethical Business Practice

(https://www.ethicalmedtech.eu)

If you have any questions about these arrangements or processes, please do not hesitate to contact us at [email protected]

A full list of our industry partners and their support can be found on the BSACI website www.bsaci.org/about-bsaci/partnership-working/

11363 TAK Ad Design_200x143mm v0.3 outlined.indd 1 29/03/2022 11:33

87wao-bsaci.org

11363 TAK Ad Design_200x143mm v0.3 outlined.indd 1 29/03/2022 11:33

Our Industry PartnersSponsors and exhibitors

Platinum Sponsors

Bronze Sponsors

Gold Sponsors

Exhibitors

Silver Sponsors


Sponsor and exhibitor profiles

Aimmune stand B2

Aimmune Therapeutics is a biopharmaceutical company that aspires to be a global leader in developing innovative medicines to prevent, manage, and treat food, gastrointestinal (GI), and metabolic-related diseases for those with few or no treatment options. For more information, please visit www.aimmune.co.uk

Allergy Therapeutics stand B8

We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments. We believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms. Driving convenience; our ultra-short course treatments make life easier and increase adherence.

ALK stand A9

ALK is a global allergy solutions company, with a wide range of allergy treatments, products and services that meet the unique needs of allergy sufferers, their families and healthcare professionals. Since 1923, when pharmacist Peter Barfod and physician Kaj Baagøe documented the first pharmaceutically manufactured allergy preparation, ALK has led the way in allergy treatment, and our long history of ‘firsts’ include demonstrating how to manufacture allergen extracts, establishing a standardised method for large-scale manufacturing, and introducing new, more convenient treatment formulations. ALK recognises that living with uncontrolled allergy impacts everyday life. As a world leader within allergy immunotherapy, ALK works to improve quality of life for allergy sufferers whose disease remains uncontrolled despite the use of symptom-relieving medication. We do this by developing products that provide long-lasting relief. ALK allergy immunotherapy products include subcutaneous injections and sublingual tablets along with an adrenaline auto-injector and products used in the diagnosis of allergies.

Learn more on ALK at www.alk.net/uk/2022-250C March 2022

Exhibitor stands can be located using the floor plan on page 101

www.aimmune.co.uk

www.allergytherapeutics.com

www.alk.net/uk

89wao-bsaci.org

Allergy UK stand A2

Allergy UK is the leading UK charity supporting the allergic community. Our mission is to raise the profile of allergy at all levels by engaging with policy makers, professional bodies, healthcare professionals and corporates towards our vision for everyone affected by allergy to receive optimal care and support.

www.allergyuk.org

Anaphylaxis stand F5

We are the only UK wide charity operating solely for the growing numbers of people at risk from severe allergic reactions and anaphylaxis. Our aim is to create a safe environment for all people with allergies by working with and educating the food industry, schools, pre-schools, colleges, health professionals and other key audiences.

Follow us on twitter @anaphylaxiscoms and find us on Facebook, LinkedIn, Instagram and YouTube.

www.anaphylaxis.org.uk

BioCryst stand B9

BioCryst is a commercial-stage biotech committed to rare diseases. With our structure-guided drug design, we’re developing novel, small-molecule, oral medicines to help people living with rare diseases take part in the everyday activities they enjoy. For more information, please visit the BioCryst team on stand B9.

www.biocryst.co.uk


The British Society for Allergy & Clinical Immunology stand B1

The British Society for Allergy & Clinical Immunology (BSACI) is the national, professional and academic society which represents the specialty of allergy at all levels. Its aim is to improve the management of allergies and related diseases of the immune system in the United Kingdom, through education, training and research.

Bio-Diagnostics stand C7

Bio-Diagnostics specialise in Allergy Diagnosis and Allergen Immunotherapy distributing high quality products from Inmunotek, SmartPractice and Lincoln Diagnostics. We also have the RhinoLight, a treatment for Seasonal and Perennial Allergic Rhinitis and ALEX a quantitative blood test for >300 allergens and components – NOW AVAILABLE AS A HOME BLEED SERVICE.

www.bsaci.org

www.bio-diagnostics.co.uk

Registry for Immunotherapy (BRIT) and UK Anaphylaxis Registry stand B3

Each BSACI registry is used to evaluate and improve outcomes for patients.

UK Fatal Anaphylaxis Registry (UKFAR) exists to collect information pertaining to fatal anaphylactic reactions with the aim of analysing the data and sharing the findings in order to influence clinical outcomes.

Registry for Immunotherapy (BRIT) is a web-based patient registry that records immunotherapy treatment of patients under the care of BSACI consultants practicing in the UK.

UK Anaphylaxis Registry has been set up to collect data relating to unintended allergic reactions. The Registry is fully integrated into the existing European Anaphylaxis Registry Network for Online Registration of Anaphylaxis (NORA).

www.bsaci.org/professional-resources/bsaci-registries/

91wao-bsaci.org

Captium stand A1

Captium Limited is a distributor focused in respiratory and working with companies including Lofarma with tablet immunotherapy and skin prick tests as well as Minaris (formerly Hitachi Diagnostics) in allergy diagnosis.

Clinical & Experimental Allergy Journal stand B1

Clinical & Experimental Allergy strikes a balance between clinical and scientific articles publishing reviews, topical editorials, original articles and BSACI Guidelines, written by leading authorities in their field. Published by Wiley on behalf of the BSACI, with an impact factor of 5.018, CEA strives to disseminate the highest quality content in the shortest possible timeframe. Please do come to the CEA/BSACI stand if you wish to talk with us about any issues around CEA. If we are not present, please leave a message with staff on the BSACI stand as our aim as Editors is to be on the stand during the breaks.

www.captium.co.uk

www.bsaci.org/publications/journals

Diagenics stand A3

Diagenics Ltd specialises in the distribution and technical support of allergy testing, diagnostic test kits, mite-proof bedding and eczema dressing. Our extensive range of products and services is tailored to meet all the needs of allergy sufferers, healthcare professionals and biomedical researchers both within the UK and internationally.

DBV Technologies no stand

DBV Technologies is a global biopharmaceutical company that’s developing an investigational epicutaneous immunotherapy (EPIT™) treatment option for the millions of people suffering from life-threatening food allergies and other immunological disorders. Starting with peanut, we are investigating food allergy treatments that are designed to potentially reduce the risk of unpredictable, life-threatening reactions due to accidental exposure.

www.diagenics.co.uk

www.dbv-technologies.com


InBio stand C6

Whether you conduct primary research on allergens, develop diagnostic systems, or create products to alleviate environmental and food allergies, you need expertise in action. And that’s exactly what InBio delivers, across everything from highly purified allergens and advanced test kits, to environmental and food allergen testing, to contract research for specialised needs.

www.inbio.com

IQAS/RCP stand A8

IQAS and QPIDS are accreditation programmes run by the RCP which assess services against a set of standards. Our aim is to promote improvement in allergy and immunodeficiency services across the UK, as accreditation plays an important role in driving change in many areas of healthcare.

www.iqas.org.uk www.qpids.org.uk

Glenmark Pharmaceuticals Europe Limited stand B10

Our mission at Glenmark Respiratory UK is to be a consistent presence in the UK respiratory market with an unwavering focus on patients. We believe in working with healthcare providers to help overcome barriers they face. We value simplicity and efficiency, values that are upheld by our respiratory brands.

www.glenmarkpharma.co.uk

EOS Network Eosinophilic Diseases Charity stand F2

Our mission Is to ensure that every person with an Eosinophilic Gastrointestinal Disease receives a prompt accurate diagnosis, the right treatment for them, and support to live with their condition. Full details of our patient resources and free registration to our global healthcare professional network can be found at www.eosnetwork.org

www.eosnetwork.org

93wao-bsaci.org

Natasha Allergy Research Foundation stand F3

The mission of the Natasha Allergy Research Foundation is to make allergy history. We want to prevent and eradicate allergic disease and create a world that is safe for all. We bring about positive change by focusing on medical research, policy change, education and raising allergy awareness.

Novartis stand A5

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we strive to use innovative science and digital technologies to create treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. In the UK, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis. Since 2014, Novartis has invested over £200 million in R&D and is a leading sponsor of clinical trials, in the UK.

For more information, please visit www.novartis.co.uk.

Novartis UK is on Twitter. Sign up to follow @NovartisUK at www.twitter.com/novartisuk.

www.narf.org.uk

www.novartis.co.uk

Mast Cell Action stand A7

MAST CELL ACTION is a new UK charity for people suffering from Mast Cell Activation Disorders (MCAD) arising from the inappropriate release of mast cell mediators, for which there is limited knowledge or treatment. We provide support for patients and their doctors, raise awareness of MCAD and fund research.

www.mastcellaction.org


Takeda stand B12

Takeda Pharmaceutical Company Limited is headquartered in Japan and is a global, values-based, R&D-driven biopharmaceutical leader. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. Our employees are committed to improving quality of life for patients.

www.takeda.com/en-gb

Scope Eyecare stand A11

Scope is a family-run company for three generations with a heritage of bringing evidence-based, premium products to healthcare professionals and end-consumers alike. Scope offers innovative Ocular Surface Disease Management Dry Eye and Blepharitis products. Scope operates in both the United Kingdom Ireland and now the USA.

www.scopeeyecare.com

Reckitt Benckiser stand A4

At Reckitt, our brands fall into three categories: Hygiene, Health and Nutrition. Our world class brands share the simple goals to Protect, Heal and Nurture. With a wealth of expertise and innovation behind every product, individuals, families and communities trust Reckitt brands to help them enjoy a cleaner, healthier life.

www.reckitt.co.uk

95wao-bsaci.org

The Allergy Team stand F4

The Allergy Team is a community of allergy parents and medical professionals, delivering accessible information and support to families. We also deliver training to schools and food businesses which builds an emotional connection. Founded by allergy mum, Sarah Knight, The Allergy Team focuses on mental wellbeing, inclusivity and positive messaging. The Allergy Team is a community of allergy parents and medical professionals, delivering accessible information and support to families. We also deliver training to schools and food businesses which builds an emotional connection. Founded by allergy mum, Sarah Knight, The Allergy Team focuses on mental wellbeing, inclusivity and positive messaging.

www.theallergyteam.com

Thermo Fisher Scientific stand A12

As a global leader in allergy and autoimmune disease diagnostics, we are committed to providing accurate, clinically relevant testing solutions to aid in the proper disease diagnosis and patient management. We are pioneers in allergy diagnostics with more than 50 years of experience in allergen production and specific IgE product development. Our products are documented in more than 6,000 publications and referenced in multiple health guidelines. These may be some of the reasons for ImmunoCAP™ being acknowledged as the gold standard technology for specific IgE blood testing. EliA™ tests provide a clinically relevant, accurate, and continuously growing autoimmune disease test portfolio on reliable laboratory systems with scalable instrument solutions for different throughput needs.

www.thermofisher.com/phadia/gb/en/our-solutions.html


World Allergy Organization stand B5

The organization was founded in 1951 and has successfully organized 25 major congresses. WAO also sponsors scientific symposia in developing areas throughout the world and jointly sponsors postgraduate programs on allergy and clinical immunology during professional, non-allergy association congresses. The World Allergy Organization’s mission, as a world-wide alliance of allergy and clinical immunology societies, is to be a global resource and advocate for the specialty, advancing awareness and excellence in clinical care through education, research, and training. WAO publishes the World Allergy Organization Journal (WAO Journal); 2020 IF 4.084.

www.worldallergy.org

Viatris stand C5

Viatris is a global pharmaceutical company, founded amid the COVID-19 pandemic and at a time of evolving healthcare needs and with a mission to empower people to live healthier at every stage of life, regardless of geography or circumstance. Operational since November 2020 following the combination of two global pharmaceutical companies, Viatris has strong roots in the UK where they have had a presence for more than six decades. The second largest pharmaceutical company in the country (based on value and volume), Viatris has an extensive portfolio of nearly 300 products across a broad range of therapeutic areas that delivers significant value to the NHS and for UK patients.

www.viatris.co.uk

97wao-bsaci.org

Industry satellite symposia


Treating peanut allergy with oral immunotherapy: implementation and practical experienceAimmune Scientific Symposium 25 April 17:45 – 18:45

Chaired by: Jonathan Hourihane, Ireland

Speakers: Janet Beausoleil, USA Caroline Nilsson, Sweden

Precision diagnostics: Precision medicineUnited airway / Biomarkers / Allergen specific immunotherapy

Thermo Fisher Scientific Symposium

25 April 12:45 – 13:45

Chaired by: Dr Glenis Scadding

Speakers: Puzzling patient management Dr Dermot Ryan Biomarker benefits Dr Mohamed Shamji

99wao-bsaci.org

I know it works, I think it works, I hope it worksAre we following the evidence base when prescribing allergen immunotherapy?ALK Scientific Symposium26 April 12:45 – 13:45

Chaired by: Dr Shuaib Nasser, Consultant in allergy and asthma, Cambridge University Hospitals

NHS Foundation TrustSpeakers: Allergen Immunotherapy and Asthma

Prof J. Christian Virchow FRCP, FCCP, FAAAAIDepartments of Pneumology / Intensive Care Medicine/ Center for Internal Medicine, University Hospital Rostock, GermanyEvidence Based ImmunotherapyPéter Csonka, M.D., Ph.D., Head of Paediatrics Terveystalo Healthcare, Finland

BSACI Registry for Immunotherapy (BRIT)Does your centre use aero-allergen, venom or peanut immunotherapy or treat chronic urticaria?

Why BRIT?• Designed by consultants for consultants to help busy allergy services across the UK• Allows patients and their clinicians to see if their treatment is working• Centres can access their data at the touch of a button• IQAS accreditation recommend the use of BRIT for allergy centres• Improving access to allergy services across the UK and quality of care• Although BRIT registered consultants must be BSACI members, their delegate

users don’t have to be

Have you registered yet? Already registered but not utilising BRIT?

brit.e-dendrite.comIn collaboration with

BSACI BRIT Registry advert (200mm x 143mm).indd 1 30/03/2022 17:25


WAO & BSACI Meeting Exhibition

Catering

Catering

Speaker's Corner

Catering

Catering

Catering

Cat

erin

g

A9

A5A2

A1

B2

A7

A3

A4

C7

C5

B1

A11 A12

B9

F5F4

C6

B10

B8

B12

B3

A8

F2 F3

B5

ExhibitorsA1 CaptiumA2 Allergy UKA3 DiagenicsA4 Reckitt BenckiserA5 NovartisA7 Mast Cell ActionA8 IQAS/RCPA9 ALKA11 Scope EyecareA12 Thermo Fisher

Scientific

B1 BSACI/CEA JournalB2 AimmuneB3 Registries for

Immunotherapy & Anaphylaxis

B5 World Allergy Organization (WAO)

B8 Allergy TherapeuticsB9 BioCrystB10 Glenmark

Pharmaceuticals

B12 TakedaC5 ViatrisC6 InBioC7 Bio-DiagnosticsF2 EOS Network F3 Natasha Allergy

Research FoundationF4 The Allergy TeamF5 Anaphylaxis

Campaign

Exhibitor floor plan

2022-279C March 2022

bsaciAnnual Conference

20235th - 7th October

BRIT

ISH S

OCIETY

FOR A

LLERGY & CLINICAL IMMUNO

LOGY

Harrogate Convention Centre

UK

SAVE THE DATE 2023 Annual Conference

5th - 7th October

2022 UK Conference - BSACI Conference 2022

Documents

Transcript of 2022 UK Conference - BSACI Conference 2022